US20160083343A1 - Compounds and uses thereof for the modulation of hemoglobin - Google Patents
Compounds and uses thereof for the modulation of hemoglobin Download PDFInfo
- Publication number
- US20160083343A1 US20160083343A1 US14/776,726 US201414776726A US2016083343A1 US 20160083343 A1 US20160083343 A1 US 20160083343A1 US 201414776726 A US201414776726 A US 201414776726A US 2016083343 A1 US2016083343 A1 US 2016083343A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- optionally substituted
- independently
- aryl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 B.C.CC[Y]C.[3*]CCC.[H]C(C)(C)C Chemical compound B.C.CC[Y]C.[3*]CCC.[H]C(C)(C)C 0.000 description 35
- OILJIEKQCVHNMM-UHFFFAOYSA-N CC(C)(C)N1CCOCC1 Chemical compound CC(C)(C)N1CCOCC1 OILJIEKQCVHNMM-UHFFFAOYSA-N 0.000 description 7
- UATQYOIOJJNROK-UHFFFAOYSA-N CC.CC(C)(C)C1(C(C)(C)C)CCCC1 Chemical compound CC.CC(C)(C)C1(C(C)(C)C)CCCC1 UATQYOIOJJNROK-UHFFFAOYSA-N 0.000 description 7
- SWGKVCAHLOUNNO-WFAYODGISA-N Cl.O=C(C1=CC=NC=C1)N1CCC[C@H]1CO.O=C(Cl)C1=CN=CC=C1.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1C(=O)C1=CC=NC=C1 Chemical compound Cl.O=C(C1=CC=NC=C1)N1CCC[C@H]1CO.O=C(Cl)C1=CN=CC=C1.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1C(=O)C1=CC=NC=C1 SWGKVCAHLOUNNO-WFAYODGISA-N 0.000 description 2
- DGXAGETVRDOQFP-UHFFFAOYSA-N Oc1c(C=O)c(O)ccc1 Chemical compound Oc1c(C=O)c(O)ccc1 DGXAGETVRDOQFP-UHFFFAOYSA-N 0.000 description 2
- JLFHXNINERBPLZ-HNNXBMFYSA-N [H]C(=O)C1=C(OC[C@@H]2CCCCN2C(=O)C2=C(C)N=CC=C2)C=CC=C1O Chemical compound [H]C(=O)C1=C(OC[C@@H]2CCCCN2C(=O)C2=C(C)N=CC=C2)C=CC=C1O JLFHXNINERBPLZ-HNNXBMFYSA-N 0.000 description 2
- MEUVAJXZPZEGQD-UHFFFAOYSA-N B.C Chemical compound B.C MEUVAJXZPZEGQD-UHFFFAOYSA-N 0.000 description 1
- KULFLGZFPGYITK-ZWWVWGPZSA-N C.C.CC1=CC=CC(OC[C@@H]2CCCCN2C(=O)C2=CN=CC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2C(=O)C2=CC=NN2C(C)C)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2S(=O)(=O)C2=CC=CC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2S(=O)(=O)C2=CN=CC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2COCCN2C(=O)C2=CC=CC=C2)=C1C=O Chemical compound C.C.CC1=CC=CC(OC[C@@H]2CCCCN2C(=O)C2=CN=CC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2C(=O)C2=CC=NN2C(C)C)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2S(=O)(=O)C2=CC=CC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2S(=O)(=O)C2=CN=CC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2COCCN2C(=O)C2=CC=CC=C2)=C1C=O KULFLGZFPGYITK-ZWWVWGPZSA-N 0.000 description 1
- GBSHGSRKSOHXPV-UHFFFAOYSA-N C.CC(=O)C1(CN2CCCCC2)CCCC1.CC(C)(C)C(=O)C1(CN2CCCCC2)CC1.CC(C)(C)C(=O)C1(CN2CCCCC2)CCC1.CC(C)(C)C(=O)C1(CN2CCCCC2)CCCCC1.CC(C)(C)C(=O)C1(CN2CCCCC2)CCOCC1.CC(C)(C)C(=O)C1(CN2CCCCC2)CCSCC1.CC(C)(C)C(=O)CCN1CCCCC1.CC(C)(C)C(=O)OCC(C)(C)N1CCOCC1.CC(C)(CN1CCOCC1)OC(=O)C(C)(C)C.CC(C)(CN1CCOCC1)OC(=O)C(C)(C)C.CC(CC(=O)C(C)(C)C)N1CCCCC1 Chemical compound C.CC(=O)C1(CN2CCCCC2)CCCC1.CC(C)(C)C(=O)C1(CN2CCCCC2)CC1.CC(C)(C)C(=O)C1(CN2CCCCC2)CCC1.CC(C)(C)C(=O)C1(CN2CCCCC2)CCCCC1.CC(C)(C)C(=O)C1(CN2CCCCC2)CCOCC1.CC(C)(C)C(=O)C1(CN2CCCCC2)CCSCC1.CC(C)(C)C(=O)CCN1CCCCC1.CC(C)(C)C(=O)OCC(C)(C)N1CCOCC1.CC(C)(CN1CCOCC1)OC(=O)C(C)(C)C.CC(C)(CN1CCOCC1)OC(=O)C(C)(C)C.CC(CC(=O)C(C)(C)C)N1CCCCC1 GBSHGSRKSOHXPV-UHFFFAOYSA-N 0.000 description 1
- NRTBSFDZQTVOGB-OBGAFBMLSA-N C.CC1=C(C(=O)N2CCCC[C@H]2COC2=C(C=O)C(O)=CC=C2)C=CC=N1.CC1=NC=C(C(=O)N2CCCC[C@H]2COC2=C(C=O)C(O)=CC=C2)C=C1 Chemical compound C.CC1=C(C(=O)N2CCCC[C@H]2COC2=C(C=O)C(O)=CC=C2)C=CC=N1.CC1=NC=C(C(=O)N2CCCC[C@H]2COC2=C(C=O)C(O)=CC=C2)C=C1 NRTBSFDZQTVOGB-OBGAFBMLSA-N 0.000 description 1
- NNAASTKINCEGDX-UHFFFAOYSA-N C.CC1=C(OCC2CN(C)CCN2C(=O)OC(C)C)C=CC=C1O.CC1=C(OCC2COCCN2C(=O)OC(C)C)C=CC=C1O.CC1=C(OCC2CSCCN2C(=O)OC(C)C)C=CC=C1O.CNC(=O)c1c(COC2=C(C)C(O)=CC=C2)CCCC1 Chemical compound C.CC1=C(OCC2CN(C)CCN2C(=O)OC(C)C)C=CC=C1O.CC1=C(OCC2COCCN2C(=O)OC(C)C)C=CC=C1O.CC1=C(OCC2CSCCN2C(=O)OC(C)C)C=CC=C1O.CNC(=O)c1c(COC2=C(C)C(O)=CC=C2)CCCC1 NNAASTKINCEGDX-UHFFFAOYSA-N 0.000 description 1
- SAKYBRJKRFABLA-UHFFFAOYSA-N C=C1OC=C(COC(=O)OC(C)(C)C)O1.C=C1OC=C(COC(C)(C)C)O1.CC(C)(C)OC(=O)OCN1C(=O)C2=C(C=CC=C2)C1=O.CC(C)(C)OCN1C(=O)C2=C(C=CC=C2)C1=O Chemical compound C=C1OC=C(COC(=O)OC(C)(C)C)O1.C=C1OC=C(COC(C)(C)C)O1.CC(C)(C)OC(=O)OCN1C(=O)C2=C(C=CC=C2)C1=O.CC(C)(C)OCN1C(=O)C2=C(C=CC=C2)C1=O SAKYBRJKRFABLA-UHFFFAOYSA-N 0.000 description 1
- MQAVAXZCKHTGER-UHFFFAOYSA-N CC(=O)C1=C(OCC2CCCN2C(=O)N2CCCC2)C=CC=C1O.CC1=C(OCC2=CC=CN=C2C(=O)N(C)C2CC2)C=CC=C1O.CC1=C(OCC2=CC=CN=C2C(=O)N2CCC2)C=CC=C1O.CC1=C(OCC2=CC=CN=C2C(=O)N2CCCC2)C=CC=C1O.CC1=C(OCC2=CC=CN=C2C(=O)N2CCCC2)C=NC=C1Cl.CC1=C(OCC2=CC=CN=C2C(=O)NC(C)C)C=CC=C1O.CC1=CN=CC(OCC2=CC=CN=C2C(=O)N2CCCC2)=C1C.CCOC(=O)N1CCCC1COC1=C(C)C(O)=CC=C1 Chemical compound CC(=O)C1=C(OCC2CCCN2C(=O)N2CCCC2)C=CC=C1O.CC1=C(OCC2=CC=CN=C2C(=O)N(C)C2CC2)C=CC=C1O.CC1=C(OCC2=CC=CN=C2C(=O)N2CCC2)C=CC=C1O.CC1=C(OCC2=CC=CN=C2C(=O)N2CCCC2)C=CC=C1O.CC1=C(OCC2=CC=CN=C2C(=O)N2CCCC2)C=NC=C1Cl.CC1=C(OCC2=CC=CN=C2C(=O)NC(C)C)C=CC=C1O.CC1=CN=CC(OCC2=CC=CN=C2C(=O)N2CCCC2)=C1C.CCOC(=O)N1CCCC1COC1=C(C)C(O)=CC=C1 MQAVAXZCKHTGER-UHFFFAOYSA-N 0.000 description 1
- VESKJZQSILVCLA-GUHKXDMSSA-N CC(C)(C)/C=C\C=O.CC1=C(C(C)(C)C)C=CC=C1O Chemical compound CC(C)(C)/C=C\C=O.CC1=C(C(C)(C)C)C=CC=C1O VESKJZQSILVCLA-GUHKXDMSSA-N 0.000 description 1
- VOMFOIJTKPSTTA-UHFFFAOYSA-N CC(C)(C)C(=O)OC1(CN2CCCCC2)CC1.CC(C)(C)C(=O)OC1(CN2CCCCC2)CCCC1.CC(C)(C)C(=O)OC1(CN2CCCCC2)CCCCC1.CC(C)(C)C(=O)OC1(CN2CCCCC2)CCOCC1.CC(C)(C)C(=O)OC1(CN2CCCCC2)CCSCC1.CC(C)(C)C(=O)OC1(CN2CCOCC2)CCC1.CC(C)(C)C(=O)OCC(C)(C)N1CCCCC1.CC(C)(C)C(=O)OCCN1CCCCC1.CC(COC(=O)C(C)(C)C)N1CCCCC1 Chemical compound CC(C)(C)C(=O)OC1(CN2CCCCC2)CC1.CC(C)(C)C(=O)OC1(CN2CCCCC2)CCCC1.CC(C)(C)C(=O)OC1(CN2CCCCC2)CCCCC1.CC(C)(C)C(=O)OC1(CN2CCCCC2)CCOCC1.CC(C)(C)C(=O)OC1(CN2CCCCC2)CCSCC1.CC(C)(C)C(=O)OC1(CN2CCOCC2)CCC1.CC(C)(C)C(=O)OCC(C)(C)N1CCCCC1.CC(C)(C)C(=O)OCCN1CCCCC1.CC(COC(=O)C(C)(C)C)N1CCCCC1 VOMFOIJTKPSTTA-UHFFFAOYSA-N 0.000 description 1
- TZBJZDUPVUWTAL-UHFFFAOYSA-N CC(C)(C)C(=O)OCOP(C)(=O)O.COP(=O)(O)OCOC(=O)C(C)(C)C Chemical compound CC(C)(C)C(=O)OCOP(C)(=O)O.COP(=O)(O)OCOC(=O)C(C)(C)C TZBJZDUPVUWTAL-UHFFFAOYSA-N 0.000 description 1
- XCYVLZXWLBLNID-UHFFFAOYSA-N CC(C)(C)C1=CC2=C(C=C1)CCCC2 Chemical compound CC(C)(C)C1=CC2=C(C=C1)CCCC2 XCYVLZXWLBLNID-UHFFFAOYSA-N 0.000 description 1
- DUEWVSVNRHEQQF-UHFFFAOYSA-N CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=N1.CC(C)(C)C1=CC=NC=C1.CC(C)(C)C1=CN=CC=C1.CC(C)N1N=CC=C1C(C)(C)C Chemical compound CC(C)(C)C1=CC=CC=C1.CC(C)(C)C1=CC=CC=N1.CC(C)(C)C1=CC=NC=C1.CC(C)(C)C1=CN=CC=C1.CC(C)N1N=CC=C1C(C)(C)C DUEWVSVNRHEQQF-UHFFFAOYSA-N 0.000 description 1
- ATADKLRTGCDSCA-UHFFFAOYSA-N CC(C)(C)C1=NC2=C(C=C1)CCCC2 Chemical compound CC(C)(C)C1=NC2=C(C=C1)CCCC2 ATADKLRTGCDSCA-UHFFFAOYSA-N 0.000 description 1
- FCXYHCYNCWKCOS-UHFFFAOYSA-N CC(C)(C)C1CCC2=C(C=CC=C2)C1 Chemical compound CC(C)(C)C1CCC2=C(C=CC=C2)C1 FCXYHCYNCWKCOS-UHFFFAOYSA-N 0.000 description 1
- BIQBSUXXWXMZCC-UHFFFAOYSA-N CC(C)(C)C1CCC2=C(C=CC=C2)N1 Chemical compound CC(C)(C)C1CCC2=C(C=CC=C2)N1 BIQBSUXXWXMZCC-UHFFFAOYSA-N 0.000 description 1
- KUNIOYNHIDRRQB-UHFFFAOYSA-N CC(C)(C)C1CCCCN1C(C)(C)C.CC(C)(C)C1CCCN1C(C)(C)C.CC(C)(C)C1COCCN1C(C)(C)C Chemical compound CC(C)(C)C1CCCCN1C(C)(C)C.CC(C)(C)C1CCCN1C(C)(C)C.CC(C)(C)C1COCCN1C(C)(C)C KUNIOYNHIDRRQB-UHFFFAOYSA-N 0.000 description 1
- ULMPRPGWHMTLNA-UHFFFAOYSA-N CC(C)(C)O.CC(C)(C)OCOP(=O)(OC(C)(C)C)OC(C)(C)C.CC(C)(C)OP(=O)(OCCl)OC(C)(C)C.CCOP(=O)(OCC)OCCl.CCOP(=O)(OCC)OCOC(C)(C)C Chemical compound CC(C)(C)O.CC(C)(C)OCOP(=O)(OC(C)(C)C)OC(C)(C)C.CC(C)(C)OP(=O)(OCCl)OC(C)(C)C.CCOP(=O)(OCC)OCCl.CCOP(=O)(OCC)OCOC(C)(C)C ULMPRPGWHMTLNA-UHFFFAOYSA-N 0.000 description 1
- NILICNSEIMSBQY-WFAYODGISA-N CC(C)N1N=CC=C1C(=O)N1CCC[C@H]1CO.CC(C)N1N=CC=C1C(=O)O.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1C(=O)C1=CC=NN1C(C)C Chemical compound CC(C)N1N=CC=C1C(=O)N1CCC[C@H]1CO.CC(C)N1N=CC=C1C(=O)O.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1C(=O)C1=CC=NN1C(C)C NILICNSEIMSBQY-WFAYODGISA-N 0.000 description 1
- UXKRQWMPDCGRKY-AWEZNQCLSA-N CC(C)N1N=CC=C1C(=O)N1CCC[C@H]1COC1=CC=CC(O)=C1C=O Chemical compound CC(C)N1N=CC=C1C(=O)N1CCC[C@H]1COC1=CC=CC(O)=C1C=O UXKRQWMPDCGRKY-AWEZNQCLSA-N 0.000 description 1
- LKEXCZVEBMMROB-UHFFFAOYSA-N CC(C)OC(=O)C(C)CP(=O)(COC(C)C(C)C)OC1=CC=CC=C1 Chemical compound CC(C)OC(=O)C(C)CP(=O)(COC(C)C(C)C)OC1=CC=CC=C1 LKEXCZVEBMMROB-UHFFFAOYSA-N 0.000 description 1
- JDVHDQZQOLEZBM-UHFFFAOYSA-N CC.CC(C)(C)C1(C(C)(C)C)[V]([V][V])CC[V]1[V][V][V] Chemical compound CC.CC(C)(C)C1(C(C)(C)C)[V]([V][V])CC[V]1[V][V][V] JDVHDQZQOLEZBM-UHFFFAOYSA-N 0.000 description 1
- RUVZZEVVZIQGTJ-YTXYTZKLSA-N CC1=C(C(=O)N2CCCC[C@H]2CO)C=CC=N1.CC1=C(C(=O)O)C=CC=N1.Cl.OC[C@@H]1CCCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCCN1C(=O)C1=C(C)N=CC=C1 Chemical compound CC1=C(C(=O)N2CCCC[C@H]2CO)C=CC=N1.CC1=C(C(=O)O)C=CC=N1.Cl.OC[C@@H]1CCCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCCN1C(=O)C1=C(C)N=CC=C1 RUVZZEVVZIQGTJ-YTXYTZKLSA-N 0.000 description 1
- OYDAKNWPWZQJGN-UHFFFAOYSA-N CC1=C(OCC2=C(C(=O)N(C)C)SC=C2)C=CC=C1O.CC1=C(OCC2=C(C(=O)N3CCCC3)CC=C2)C=CC=C1O.CC1=C(OCC2CCCCN2C(=O)C(C)C)C=CC=C1O.CC1=C(OCc2c(C(=O)N(C)C(C)C)CCCC2)C=CC=C1O.CCCC(=O)N1CCOCC1COC1=C(C)C(O)=CC=C1.CCNC(=O)c1c(COC2=C(C)C(O)=CC=C2)COCC1 Chemical compound CC1=C(OCC2=C(C(=O)N(C)C)SC=C2)C=CC=C1O.CC1=C(OCC2=C(C(=O)N3CCCC3)CC=C2)C=CC=C1O.CC1=C(OCC2CCCCN2C(=O)C(C)C)C=CC=C1O.CC1=C(OCc2c(C(=O)N(C)C(C)C)CCCC2)C=CC=C1O.CCCC(=O)N1CCOCC1COC1=C(C)C(O)=CC=C1.CCNC(=O)c1c(COC2=C(C)C(O)=CC=C2)COCC1 OYDAKNWPWZQJGN-UHFFFAOYSA-N 0.000 description 1
- DJGGJNFWXJIHNW-DTPGYVEDSA-N CC1=CC=CC(OC[C@@H]2CCCCN2C(=O)C2=CC=CC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2C(=O)C2=CC=CC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2C(=O)C2=CC=CC=N2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2C(=O)C2=CC=NC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2C(=O)C2=CN=CC=C2)=C1C=O Chemical compound CC1=CC=CC(OC[C@@H]2CCCCN2C(=O)C2=CC=CC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2C(=O)C2=CC=CC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2C(=O)C2=CC=CC=N2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2C(=O)C2=CC=NC=C2)=C1C=O.CC1=CC=CC(OC[C@@H]2CCCN2C(=O)C2=CN=CC=C2)=C1C=O DJGGJNFWXJIHNW-DTPGYVEDSA-N 0.000 description 1
- XRFJYLJLKGFIFN-ZJMCKRPCSA-N CC1=NC=C(C(=O)N2CCCC[C@H]2CO)C=C1.CC1=NC=C(C(=O)O)C=C1.Cl.OC[C@@H]1CCCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCCN1C(=O)C1=CN=C(C)C=C1 Chemical compound CC1=NC=C(C(=O)N2CCCC[C@H]2CO)C=C1.CC1=NC=C(C(=O)O)C=C1.Cl.OC[C@@H]1CCCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCCN1C(=O)C1=CN=C(C)C=C1 XRFJYLJLKGFIFN-ZJMCKRPCSA-N 0.000 description 1
- NEIXFFJGYRWCLS-UHFFFAOYSA-N CCC(=O)OCC(C)(C)C.COCC(C)(C)C Chemical compound CCC(=O)OCC(C)(C)C.COCC(C)(C)C NEIXFFJGYRWCLS-UHFFFAOYSA-N 0.000 description 1
- PYCHXHVFOZBVEY-UHFFFAOYSA-N CCCC(=O)C(C)(C)C Chemical compound CCCC(=O)C(C)(C)C PYCHXHVFOZBVEY-UHFFFAOYSA-N 0.000 description 1
- IMSGHKWOMSVPEN-UHFFFAOYSA-N CCO.COCOC1=CC=C(O)N=C1.COCOC1=CC=C(OCC2=CC=CC=C2)N=C1 Chemical compound CCO.COCOC1=CC=C(O)N=C1.COCOC1=CC=C(OCC2=CC=CC=C2)N=C1 IMSGHKWOMSVPEN-UHFFFAOYSA-N 0.000 description 1
- SXZJBBPDJAQHNF-WTMQMJMGSA-N COC1=CC(C=O)=C(O)C=N1.COC1=CC=C(O)C=N1.COCCl.COCOC1=C(C=O)C=C(OC)N=C1.COCOC1=CC=C(OC)N=C1.[2H]CF Chemical compound COC1=CC(C=O)=C(O)C=N1.COC1=CC=C(O)C=N1.COCCl.COCOC1=C(C=O)C=C(OC)N=C1.COCOC1=CC=C(OC)N=C1.[2H]CF SXZJBBPDJAQHNF-WTMQMJMGSA-N 0.000 description 1
- CNMIRVDOESDSFA-UHFFFAOYSA-N COC1=CC=CC(OC)=C1C=O.O=CC1=C(O)C=CC=C1O Chemical compound COC1=CC=CC(OC)=C1C=O.O=CC1=C(O)C=CC=C1O CNMIRVDOESDSFA-UHFFFAOYSA-N 0.000 description 1
- ACHYQASHNVEJKM-UHFFFAOYSA-M COCCBr.COCCOC1=C(C=O)C=C(O)C=N1.COCCOC1=C(C=O)C=C(OCOC)C=N1.COCCOC1=CC(C=O)=C(O)C=N1.COCCOC1=CC(C=O)=C(OCOC)C=N1.COCCOC1=CC=C(OCOC)C=N1.COCCl.COCOC1=CC=C(O)N=C1.COCOC1=CC=C(OCC2=CC=CC=C2)N=C1.O=COO[K].OC1=CC=C(OCC2=CC=CC=C2)N=C1.[KH] Chemical compound COCCBr.COCCOC1=C(C=O)C=C(O)C=N1.COCCOC1=C(C=O)C=C(OCOC)C=N1.COCCOC1=CC(C=O)=C(O)C=N1.COCCOC1=CC(C=O)=C(OCOC)C=N1.COCCOC1=CC=C(OCOC)C=N1.COCCl.COCOC1=CC=C(O)N=C1.COCOC1=CC=C(OCC2=CC=CC=C2)N=C1.O=COO[K].OC1=CC=C(OCC2=CC=CC=C2)N=C1.[KH] ACHYQASHNVEJKM-UHFFFAOYSA-M 0.000 description 1
- IKXRGHWVYZRVFJ-DLWAKCFRSA-M COCCBr.COCCOC1=CC=C(OCOC)C=N1.COCOC1=CC=C(O)N=C1.O=COO[K].[2H]CF.[KH] Chemical compound COCCBr.COCCOC1=CC=C(OCOC)C=N1.COCOC1=CC=C(O)N=C1.O=COO[K].[2H]CF.[KH] IKXRGHWVYZRVFJ-DLWAKCFRSA-M 0.000 description 1
- XMONPNPUQTYSOW-UHFFFAOYSA-N COCCOC1=C(C=O)C=C(O)C=N1.COCCOC1=C(C=O)C=C(OCOC)C=N1.COCCOC1=CC(C=O)=C(O)C=N1.COCCOC1=CC(C=O)=C(OCOC)C=N1 Chemical compound COCCOC1=C(C=O)C=C(O)C=N1.COCCOC1=C(C=O)C=C(OCOC)C=N1.COCCOC1=CC(C=O)=C(O)C=N1.COCCOC1=CC(C=O)=C(OCOC)C=N1 XMONPNPUQTYSOW-UHFFFAOYSA-N 0.000 description 1
- CBKFGZZWYWJGAW-PBJKEDEQSA-N COCCOC1=C(C=O)C=C(OCOC)C=N1.COCCOC1=CC(C=O)=C(OCOC)C=N1.COCCOC1=CC=C(OCOC)C=N1.[2H]CF Chemical compound COCCOC1=C(C=O)C=C(OCOC)C=N1.COCCOC1=CC(C=O)=C(OCOC)C=N1.COCCOC1=CC=C(OCOC)C=N1.[2H]CF CBKFGZZWYWJGAW-PBJKEDEQSA-N 0.000 description 1
- WXSGQHKHUYTJNB-UHFFFAOYSA-N COc1cccc(OC)c1C=O Chemical compound COc1cccc(OC)c1C=O WXSGQHKHUYTJNB-UHFFFAOYSA-N 0.000 description 1
- HNTZKNJGAFJMHQ-UHFFFAOYSA-N Cc(nccc1)c1C(O)=O Chemical compound Cc(nccc1)c1C(O)=O HNTZKNJGAFJMHQ-UHFFFAOYSA-N 0.000 description 1
- ZIXSELYHQFHZIN-NSHDSACASA-N Cc1ncccc1C(N1[C@H](CO)CCCC1)=O Chemical compound Cc1ncccc1C(N1[C@H](CO)CCCC1)=O ZIXSELYHQFHZIN-NSHDSACASA-N 0.000 description 1
- VLAGVLCHJQHWTE-ZJMCKRPCSA-N Cl.O=C(C1=CC=CC=C1)N1CCCC[C@H]1CO.O=C(Cl)C1=CC=CC=C1.OC[C@@H]1CCCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCCN1C(=O)C1=CC=CC=C1 Chemical compound Cl.O=C(C1=CC=CC=C1)N1CCCC[C@H]1CO.O=C(Cl)C1=CC=CC=C1.OC[C@@H]1CCCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCCN1C(=O)C1=CC=CC=C1 VLAGVLCHJQHWTE-ZJMCKRPCSA-N 0.000 description 1
- HAHFFWYISUFQON-UATRRPIVSA-N Cl.O=C(C1=CN=CC=C1)N1CCCC[C@H]1CO.O=C(Cl)C1=CN=CC=C1.OCC1CCCCC1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCCN1C(=O)C1=CN=CC=C1 Chemical compound Cl.O=C(C1=CN=CC=C1)N1CCCC[C@H]1CO.O=C(Cl)C1=CN=CC=C1.OCC1CCCCC1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCCN1C(=O)C1=CN=CC=C1 HAHFFWYISUFQON-UATRRPIVSA-N 0.000 description 1
- RIPKLZNMXUJYBN-NNRZWQGASA-N Cl.O=C(C1=CN=CC=C1)N1CCC[C@H]1CO.O=C(Cl)C1=NC=CC=C1.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1C(=O)C1=NC=CC=C1 Chemical compound Cl.O=C(C1=CN=CC=C1)N1CCC[C@H]1CO.O=C(Cl)C1=NC=CC=C1.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1C(=O)C1=NC=CC=C1 RIPKLZNMXUJYBN-NNRZWQGASA-N 0.000 description 1
- UEQPLKMWJVGYBT-YOSHPDDESA-N Cl.O=S(=O)(C1=CN=CC=C1)N1CCC[C@H]1CO.O=S(=O)(Cl)C1=CC=CN=C1.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1S(=O)(=O)C1=CN=CC=C1 Chemical compound Cl.O=S(=O)(C1=CN=CC=C1)N1CCC[C@H]1CO.O=S(=O)(Cl)C1=CC=CN=C1.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1S(=O)(=O)C1=CN=CC=C1 UEQPLKMWJVGYBT-YOSHPDDESA-N 0.000 description 1
- SCXSPILKCOEGAD-DKHBGXPNSA-N O=C(C1=CC=CC=C1)N1CCC[C@H]1CO.O=C(Cl)C1=CC=CC=C1.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1C(=O)C1=CC=CC=C1 Chemical compound O=C(C1=CC=CC=C1)N1CCC[C@H]1CO.O=C(Cl)C1=CC=CC=C1.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1C(=O)C1=CC=CC=C1 SCXSPILKCOEGAD-DKHBGXPNSA-N 0.000 description 1
- NPBLPRWHAIRUFM-QLRNWHNBSA-N O=C(C1=CC=CC=C1)N1CCOC[C@H]1CO.O=C(Cl)C1=CC=CC=C1.OC[C@H]1CCCOC1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1COCCN1C(=O)C1=CC=CC=C1 Chemical compound O=C(C1=CC=CC=C1)N1CCOC[C@H]1CO.O=C(Cl)C1=CC=CC=C1.OC[C@H]1CCCOC1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1COCCN1C(=O)C1=CC=CC=C1 NPBLPRWHAIRUFM-QLRNWHNBSA-N 0.000 description 1
- ZZQQDMLLINNERD-WFAYODGISA-N O=S(=O)(C1=CC=CC=C1)N1CCC[C@H]1CO.O=S(=O)(Cl)C1=CC=CC=C1.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1S(=O)(=O)C1=CC=CC=C1 Chemical compound O=S(=O)(C1=CC=CC=C1)N1CCC[C@H]1CO.O=S(=O)(Cl)C1=CC=CC=C1.OC[C@@H]1CCCN1.[H]C(=O)C1=C(O)C=CC=C1O.[H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1S(=O)(=O)C1=CC=CC=C1 ZZQQDMLLINNERD-WFAYODGISA-N 0.000 description 1
- PRAYXGYYVXRDDW-LURJTMIESA-N OC[C@H]1NCCCC1 Chemical compound OC[C@H]1NCCCC1 PRAYXGYYVXRDDW-LURJTMIESA-N 0.000 description 1
- OTNHCDMTINHDPR-INIZCTEOSA-N [H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCCN1C(=O)C1=CC=CC=C1 Chemical compound [H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCCN1C(=O)C1=CC=CC=C1 OTNHCDMTINHDPR-INIZCTEOSA-N 0.000 description 1
- AOMVIQXGKMTHAH-HNNXBMFYSA-N [H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1C(=O)C1=CC=CC=C1 Chemical compound [H]C(=O)C1=C(O)C=CC=C1OC[C@@H]1CCCN1C(=O)C1=CC=CC=C1 AOMVIQXGKMTHAH-HNNXBMFYSA-N 0.000 description 1
- RYLYOEVKMYTDQA-INIZCTEOSA-N [H]C(=O)C1=C(OC[C@@H]2CCCCN2C(=O)C2=CN=C(C)C=C2)C=CC=C1O Chemical compound [H]C(=O)C1=C(OC[C@@H]2CCCCN2C(=O)C2=CN=C(C)C=C2)C=CC=C1O RYLYOEVKMYTDQA-INIZCTEOSA-N 0.000 description 1
- DIXJEEIWNGTEBR-HNNXBMFYSA-N [H]C(=O)C1=C(OC[C@@H]2CCCCN2C(=O)C2=CN=CC=C2)C=CC=C1O Chemical compound [H]C(=O)C1=C(OC[C@@H]2CCCCN2C(=O)C2=CN=CC=C2)C=CC=C1O DIXJEEIWNGTEBR-HNNXBMFYSA-N 0.000 description 1
- USYDBTWWZXXXES-AWEZNQCLSA-N [H]C(=O)C1=C(OC[C@@H]2CCCN2C(=O)C2=CC=NC=C2)C=CC=C1O Chemical compound [H]C(=O)C1=C(OC[C@@H]2CCCN2C(=O)C2=CC=NC=C2)C=CC=C1O USYDBTWWZXXXES-AWEZNQCLSA-N 0.000 description 1
- LAEUDKTWJROGLP-AWEZNQCLSA-N [H]C(=O)C1=C(OC[C@@H]2CCCN2C(=O)C2=CN=CC=C2)C=CC=C1O Chemical compound [H]C(=O)C1=C(OC[C@@H]2CCCN2C(=O)C2=CN=CC=C2)C=CC=C1O LAEUDKTWJROGLP-AWEZNQCLSA-N 0.000 description 1
- TWOOAJJERQIUND-ZDUSSCGKSA-N [H]C(=O)C1=C(OC[C@@H]2CCCN2C(=O)C2=NC=CC=C2)C=CC=C1O Chemical compound [H]C(=O)C1=C(OC[C@@H]2CCCN2C(=O)C2=NC=CC=C2)C=CC=C1O TWOOAJJERQIUND-ZDUSSCGKSA-N 0.000 description 1
- NYDZWFBXOVCAIM-AWEZNQCLSA-N [H]C(=O)C1=C(OC[C@@H]2CCCN2S(=O)(=O)C2=CC=CC=C2)C=CC=C1O Chemical compound [H]C(=O)C1=C(OC[C@@H]2CCCN2S(=O)(=O)C2=CC=CC=C2)C=CC=C1O NYDZWFBXOVCAIM-AWEZNQCLSA-N 0.000 description 1
- AWTCNJQMMIGYMR-ZDUSSCGKSA-N [H]C(=O)C1=C(OC[C@@H]2CCCN2S(=O)(=O)C2=CC=CN=C2)C=CC=C1O Chemical compound [H]C(=O)C1=C(OC[C@@H]2CCCN2S(=O)(=O)C2=CC=CN=C2)C=CC=C1O AWTCNJQMMIGYMR-ZDUSSCGKSA-N 0.000 description 1
- SXAADVVBQKBOHZ-HNNXBMFYSA-N [H]C(=O)C1=C(OC[C@@H]2COCCN2C(=O)C2=CC=CC=C2)C=CC=C1O Chemical compound [H]C(=O)C1=C(OC[C@@H]2COCCN2C(=O)C2=CC=CC=C2)C=CC=C1O SXAADVVBQKBOHZ-HNNXBMFYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention provides compounds and pharmaceutical compositions suitable as allosteric modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
- Sickle cell disease is a disorder of the red blood cells, found particularly among those of African and Mediterranean descent.
- the basis for sickle cell disease is found in sickle hemoglobin (HbS), which contains a point mutation relative to the prevalent peptide sequence of hemoglobin (Hb).
- Hemoglobin transports oxygen molecules from the lungs to various tissues and organs throughout the body. Hemoglobin binds and releases oxygen through conformational changes.
- Sickle hemoglobin (HbS) contains a point mutation where glutamic acid is replaced with valine, allowing HbS to become susceptible to polymerization to give the HbS containing red blood cells their characteristic sickle shape. The sickled cells are also more rigid than normal red blood cells, and their lack of flexibility can lead to blockage of blood vessels.
- U.S. Pat. No. 7,160,910 discloses compounds that are allosteric modulators of hemoglobin. However, a need exists for additional therapeutics that can treat disorders that are mediated by Hb or by abnormal Hb such as HbS.
- This invention relates generally to compounds and pharmaceutical compositions suitable as allosteric modulators of hemoglobin. In some aspects, this invention relates to methods for treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
- ring b is joined to L 1 or L 2 via a nitrogen atom.
- R 3 is joined to L 2 via a nitrogen atom.
- composition comprising any of the compounds described herein, and at least a pharmaceutically acceptable excipient.
- a method for increasing oxygen affinity of hemoglobin S in a subject comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.
- a method for treating oxygen deficiency associated with sickle cell anemia comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.
- compositions and methods are intended to mean that the compositions and methods include the recited elements, but not excluding others.
- Consisting essentially of when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition or process consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention.
- Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.
- C m -C n such as C 1 -C 12 , C 1 -C 8 , or C 1 -C 6 when used before a group refers to that group containing m to n carbon atoms.
- alkoxy refers to —O-alkyl. Cycloalkoxy refers to —O-cycloalkyl.
- alkyl refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 30 carbon atoms (i.e., C 1 -C 30 alkyl) or 1 to 22 carbon atoms (i.e., C 1 -C 22 alkyl), 1 to 8 carbon atoms (i.e., C 1 -C 8 alkyl), or 1 to 4 carbon atoms.
- This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH 3 —), ethyl (CH 3 CH 2 —), n-propyl (CH 3 CH 2 CH 2 —), isopropyl ((CH 3 ) 2 CH—), n-butyl (CH 3 CH 2 CH 2 CH 2 —), isobutyl ((CH 3 ) 2 CHCH 2 —), sec-butyl ((CH 3 )(CH 3 CH 2 )CH—), t-butyl ((CH 3 ) 3 C—), n-pentyl (CH 3 CH 2 CH 2 CH 2 CH 2 —), and neopentyl ((CH 3 ) 3 CCH 2 —).
- linear and branched hydrocarbyl groups such as methyl (CH 3 —), ethyl (CH 3 CH 2 —), n-propyl (CH 3 CH 2 CH 2 —), isopropyl ((CH 3 ) 2 CH—),
- aryl refers to a monovalent, aromatic mono- or bicyclic ring having 6-10 ring carbon atoms. Examples of aryl include phenyl and naphthyl. The condensed ring may or may not be aromatic provided that the point of attachment is at an aromatic carbon atom. For example, and without limitation, the following is an aryl group:
- —CO 2 H ester refers to an ester formed between the —CO 2 H group and an alcohol, preferably an aliphatic alcohol.
- chiral moiety refers to a moiety that is chiral. Such a moiety can possess one or more asymmetric centers. Preferably, the chiral moiety is enantiomerically enriched, and more preferably a single enantiomer.
- Non limiting examples of chiral moieties include chiral carboxylic acids, chiral amines, chiral amino acids, such as the naturally occurring amino acids, chiral alcohols including chiral steroids, and the likes.
- cycloalkyl refers to a monovalent, preferably saturated, hydrocarbyl mono-, bi-, or tricyclic ring having 3-12 ring carbon atoms. While cycloalkyl, refers preferably to saturated hydrocarbyl rings, as used herein, it also includes rings containing 1-2 carbon-carbon double bonds. Nonlimiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamentyl, and the like. The condensed rings may or may not be non-aromatic hydrocarbyl rings provided that the point of attachment is at a cycloalkyl carbon atom. For example, and without limitation, the following is a cycloalkyl group:
- halo refers to F, Cl, Br, and/or I.
- heteroaryl refers to a monovalent, aromatic mono-, bi-, or tricyclic ring having 2-16 ring carbon atoms and 1-8 ring heteroatoms selected preferably from N, O, S, and P and oxidized forms of N, S, and P, provided that the ring contains at least 5 ring atoms.
- Nonlimiting examples of heteroaryl include furan, imidazole, oxadiazole, oxazole, pyridine, quinoline, and the like.
- the condensed rings may or may not be a heteroatom containing aromatic ring provided that the point of attachment is a heteroaryl atom.
- heterocyclyl refers to a non-aromatic, mono-, bi-, or tricyclic ring containing 2-12 ring carbon atoms and 1-8 ring heteroatoms selected preferably from N, O, S, and P and oxidized forms of N, S, and P, provided that the ring contains at least 3 ring atoms. While heterocyclyl preferably refers to saturated ring systems, it also includes ring systems containing 1-3 double bonds, provided that the ring is non-aromatic.
- heterocyclyl examples include, azalactones, oxazoline, piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuranyl, and tetrahydropyranyl.
- the condensed rings may or may not contain a non-aromatic heteroatom containing ring provided that the point of attachment is a heterocyclyl group.
- the following is a heterocyclyl group:
- hydrolyzing refers to breaking an R H —O—CO—, R H —O—CS—, or an R H —O—SO 2 -moiety to an R H —OH, preferably by adding water across the broken bond.
- a hydrolyzing is performed using various methods well known to the skilled artisan, non limiting examples of which include acidic and basic hydrolysis.
- oxo refers to a C ⁇ O group, and to a substitution of 2 geminal hydrogen atoms with a C ⁇ O group.
- the group may be substituted with one or more substituents, such as e.g., 1, 2, 3, 4 or 5 substituents.
- the substituents are selected from the group consisting of oxo, halo, —CN, NO 2 , —N 2 +, —CO 2 R 100 , —OR 100 , —SR 100 , —SOR 100 , —SO 2 R 100 , —NR 101 R 102 , —CONR 101 R 102 , —SO 2 NR 101 R 102 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, —CR 100 ⁇ C(R 100 ) 2 , —CCR 100 , C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, C 6 -C 12 aryl and C 2 -C 12 heteroaryl, wherein each R 100 independently is hydrogen or C 1 -C 8 alkyl; C 3 -C 12 cycloalkyl;
- the substituents are selected from the group consisting of chloro, fluoro, —OCH 3 , methyl, ethyl, iso-propyl, cyclopropyl, vinyl, ethynyl, —CO 2 H, —CO 2 CH 3 , —OCF 3 , —CF 3 and —OCHF 2 .
- R 101 and R 102 independently is hydrogen; C 1 -C 8 alkyl, optionally substituted with —CO 2 H or an ester thereof, C 1 -C 6 alkoxy, oxo, —CR 103 ⁇ C(R 103 ) 2 , —CCR, C 3 -C 10 cycloalkyl, C 3 -C 10 heterocyclyl, C 6 -C 12 aryl, or C 2 -C 12 heteroaryl, wherein each R 103 independently is hydrogen or C 1 -C 8 alkyl; C 3 -C 12 cycloalkyl; C 3 -C 10 heterocyclyl; C 6 -C 12 aryl; or C 2 -C 12 heteroaryl; wherein each cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with 1-3 alkyl groups or 1-3 halo groups, or R 101 and R 102 together with the nitrogen atom they are attached to form a 5-7 membered heterocycle.
- pharmaceutically acceptable refers to safe and non-toxic for in vivo, preferably, human administration.
- pharmaceutically acceptable salt refers to a salt that is pharmaceutically acceptable.
- salt refers to an ionic compound formed between an acid and a base.
- salts include, without limitation, alkali metal, alkaline earth metal, and ammonium salts.
- ammonium salts include, salts containing protonated nitrogen bases and alkylated nitrogen bases.
- Exemplary, and non-limiting cations useful in pharmaceutically acceptable salts include Na, K, Rb, Cs, NH 4 , Ca, Ba, imidazolium, and ammonium cations based on naturally occurring amino acids.
- salts include, without limitation, salts of organic acids, such as carboxylic acids and sulfonic acids, and mineral acids, such as hydrogen halides, sulfuric acid, phosphoric acid, and the likes.
- exemplary and non-limiting anions useful in pharmaceutically acceptable salts include oxalate, maleate, acetate, propionate, succinate, tartrate, chloride, sulfate, bisalfate, mono-, di-, and tribasic phosphate, mesylate, tosylate, and the likes.
- treat include alleviating, abating or ameliorating a disease or condition or one or more symptoms thereof, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting or suppressing the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or suppressing the symptoms of the disease or condition, and are intended to include prophylaxis.
- the terms also include relieving the disease or conditions, e.g., causing the regression of clinical symptoms.
- the terms further include achieving a therapeutic benefit and/or a prophylactic benefit.
- compositions are administered to an individual at risk of developing a particular disease, or to an individual reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.
- preventing or “prevention” refer to a reduction in risk of acquiring a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease).
- the terms further include causing the clinical symptoms not to develop, for example in a subject at risk of suffering from such a disease or disorder, thereby substantially averting onset of the disease or disorder.
- an effective amount refers to an amount that is effective for the treatment of a condition or disorder by an intranasal administration of a compound or composition described herein.
- an effective amount of any of the compositions or dosage forms described herein is the amount used to treat a disorder mediated by hemoglobin or a disorder that would benefit from tissue and/or cellular oxygenation of any of the compositions or dosage forms described herein to a subject in need thereof.
- carrier refers to relatively nontoxic chemical compounds or agents that facilitate the incorporation of a compound into cells, e.g., red blood cells, or tissues.
- a “prodrug” is a compound that, after administration, is metabolized or otherwise converted to an active or more active form with respect to at least one property.
- a pharmaceutically active compound can be modified chemically to render it less active or inactive, but the chemical modification is such that an active form of the compound is generated by metabolic or other biological processes.
- a prodrug may have, relative to the drug, altered metabolic stability or transport characteristics, fewer side effects or lower toxicity. For example, see the reference Nogrady, 1985, Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392.
- Prodrugs can also be prepared using compounds that are not drugs.
- L 1 is a bond
- L 2 is C ⁇ O. In certain embodiments, L 2 is SO 2 .
- ring C is phenyl which is optionally substituted with 1-4: halo, oxo, —OR 2 , C 1 -C 6 alkyl and/or C 1 -C 6 alkoxy,
- V 1 and V 2 independently are C 1 -C 6 alkoxy; or V 1 and V 2 together with the carbon atom they are attached to form a ring of formula:
- t is 0. In certain embodiments, t is 1. In certain embodiments, t is 2. In certain embodiments, t is 3.
- R 60 can be hydrogen, provided that the COOR 60 is not joined to a nitrogen atom.
- Y and Z are both not a heteroatom or a heteroatom containing moiety.
- one of Y and Z is a methylene or substituted methylene and the other is a heteroatom or a heteroatom containing moiety.
- Y is an alkylene
- Z is a heteroatom or a heteroatom containing moiety, which, yet more preferably is oxygen.
- V 1 and V 2 together with the carbon atom they are attached to form a ring of formula:
- V 1 and V 2 independently are C 1 -C 6 alkoxy; or V 1 and V 2 together with the carbon atom they are attached to form a ring of formula:
- each V 3 and V 4 are independently O, S, or NH, provided that when one or V 3 and V 4 is S the other is NH, and provided that V 3 and V 4 are both not NH; q is 1 or 2; each V 5 is independently C 1 -C 6 alkyl or CO 2 R 60 , where each R 60 independently is C 1 -C 6 alkyl or hydrogen; t is 0, 1, 2, or 4; or CV 1 V 2 is C ⁇ V, wherein V is O.
- the compound of Formula (II) is of Formula (III):
- Y—Z is —CH 2 O— or —CH 2 CH 2 — and the remaining substituents are as defined herein.
- R 4 and —CHO are joined to adjacent atoms on ring C.
- the compound of Formula (II) is of Formula (IIIA):
- the compound is of Formula IIIB, IIIC, or IIID:
- ring B is substituted with 1-3: halo, C 1 -C 6 alkyl, COR 15 , or COOR 15 ;
- 2 is CH 2 , O, S, SO, SO 2 or NH.
- Z is O, S, SO or SO 2 .
- Z is O, and wherein the remaining variables are defined herein.
- Y is CR 10 R 11 , O, S, SO, SO 2 , or NR 10 ; wherein each R 10 and R 11 independently is hydrogen or C 1 -C 3 alkyl. In certain embodiments, Y is CR 10 R 11 wherein each R 10 and R 11 independently is hydrogen or C 1 -C 3 alkyl. Preferably, Y is CH 2 , and wherein the remaining variables are defined herein.
- t is 0. In certain embodiments, t is 1. In certain embodiments, t is 2. In certain embodiments, t is 3.
- CV 1 V 2 is C ⁇ V, wherein V is O, and wherein the remaining variables are defined herein.
- R 4 is —OH.
- R 3 is optionally substituted phenyl. In other embodiments, R 3 is optionally substituted pyridine. In certain embodiments, R 3 is optionally substituted pyrazole.
- R 3 is selected from the group consisting of:
- ring B is a 5-6 membered heterocycle containing a heteroatom selected from N, S, or O. In one embodiment, ring B is a 5-6 membered heterocycle containing a N as the heteroatom.
- ring B is selected from the group consisting of:
- L is a bond
- L 2 is C ⁇ O. In certain embodiments, L 2 is SO 2 .
- ring C is phenyl which is optionally substituted with 1-4: halo, oxo, —OR 2 , C 1 -C 6 alkyl and/or C 1 -C 6 alkoxy,
- the compound is selected from the group consisting of
- R is hydrogen, a phosphate or a diphosphate containing moiety, or another promoiety or prodrug moiety.
- the prodrug moiety imparts at least a 2 fold, more preferably a 4 fold, enhanced solubility and/or bioavailability to the active moiety (where R is hydrogen), and more preferably is hydrolyzed in vivo.
- the promoieties are structurally and functionally defined herein.
- R is —COR 90 , CO 2 R 91 , or CONR 92 R 93 wherein R 90 and R 91 independently are C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, each containing at least 1 basic nitrogen moiety; and
- R is —C(O)R 31 , C(O)OR 31 , or CON(R 13 ) 2 ,
- each R 31 is independently a C 1 -C 6 alkyl; C 3 -C 8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, containing at least 1 basic nitrogen moiety; and
- each R 13 independently is C 1 -C 6 alkyl; C 3 -C 8 cycloalkyl, 4-9 membered heterocycle, or a 5-10 membered heteroaryl, containing at least 1 basic nitrogen moiety; or 2 R 13 together with the nitrogen atom they are bonded to for a 4-9 member heterocycle substituted with at least 1 amino, C 1 -C 6 alkyl amino, or di C 1 -C 6 alkylamino group.
- R is C(O)OR 31 , C(S)OR 31 , C(O)SR 31 or COR 31 , wherein R 31 is as defined herein.
- R 31 is a group of the formula (CR 32 R 33 ) e NR 34 R 35 , wherein
- each R 32 and R 33 is independently H, a C 1 -C 8 alkyl, C 3 -C 9 heterocyclyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, C 3 -C 9 heteroaryl or R 32 and R 33 together with the carbon atom they are bond to form a C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, C 3 -C 9 heterocyclyl or C 3 -C 9 heteroaryl ring system, or 2 adjacent R 32 moieties or 2 adjacent R 33 moieties together with the carbon atom they are bond to form a C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, C 3 -C 9 heterocyclyl or C 3 -C 9 heteroaryl ring system;
- each R 34 and R 35 is a C 1 -C 8 alkyl, C 3 -C 9 heterocyclyl, C 3 -C 8 cycloalkyl, or R 34 and R 35 together with the nitrogen atom they are bond to form a C 3 -C 8 cycloalkyl or C 3 -C 9 heterocyclyl ring system;
- each heterocyclic and heteroaryl ring system is optionally substituted with C 1 -C 3 alkyl, —OH, amino and carboxyl groups;
- e is an integer of from 1 to 4.
- R 34 and R 35 can be hydrogen.
- the subscript e is preferably 2 and each R 32 and R 33 is preferably independently selected from the group, H, CH 3 , and a member in which R 32 and R 33 are joined together to form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 1,1-dioxo-hexahydro-I ⁇ 6 -thiopyran-4-yl or tetrahydropyran-4-yl group.
- preferred embodiments are compounds wherein NR 34 R 35 is morpholino.
- R is:
- each R 32 and R 33 is independently H, C 1 -C 8 alkyl, or optionally, if both present on the same substituent, may be joined together to form a C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, C 3 -C 9 heterocyclyl or C 3 -C 9 heteroaryl ring system.
- each R 32 and R 33 is independently, H, CH 3 , or are joined together to form a cyclopropyl, cyclopbutyl, cyclopentyl, cyclohexyl, 1,1-dioxo-hexahydro-I ⁇ 6 -thiopyran-4-yl or tetrahydropyran-4-yl group.
- linkage of the prodrug moiety to the rest of the active molecule is stable enough so that the serum half life of the prodrug is from about 8 to about 24 hours.
- the prodrug moiety comprises a tertiary amine having a pKa near the physiological pH of 7.5. Any amines having a pKa within 1 unit of 7.5 are suitable alternatives amines for this purpose.
- the amine may be provided by the amine of a morpholino group. This pKa range of 6.5 to 8.5 allows for significant concentrations of the basic neutral amine to be present in the mildly alkaline small intestine.
- the basic, neutral form of the amine prodrug is lipophilic and is absorbed through the wall of the small intestine into the blood. Following absorption into the bloodstream, the prodrug moiety is cleaved by esterases which are naturally present in the serum to release an active compound.
- R examples of R include, without limitation:
- R is as tabulated below:
- R is,
- R 36 is lower alkyl (e.g. C 1 -C 6 alkyl).
- R is:
- X 1 is selected from the group consisting of O, S and NR 37 wherein R 37 is hydrogen or C 1 -C 6 alkyl;
- Y 1 is —C(R 38 ) 2 or a sugar moiety, wherein each R 38 is independently hydrogen or C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl;
- X 2 is selected from the group consisting of halogen, C 1 -C 6 alkoxy, diacylglycerol, amino, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, C 1 -C 6 alkylthio, a PEG moiety, a bile acid moiety, a sugar moiety, an amino acid moiety, a di- or tri-peptide, a PEG carboxylic acid, and —U—V wherein
- U is O or S
- V is selected from the group consisting of C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, C 3 -C 9 heteroaryl, C(W 2 )X 3 , PO(X 3 ) 2 , and SO 2 X 3 ;
- W 2 is O or NR 39
- R 39 is hydrogen or C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 hetrocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl;
- each X 3 is independently amino, hydroxyl, mercapto, C 1 -C 6 alkyl, heteroalkyl, cycloalkyl, hetrocyclyl, aryl, or heteroaryl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, C 1 -C 6 alkylthio, a bile acid based alkoxy group, a sugar moiety, a PEG moiety, and —O—CH 2 —CH(OR 40 )CH 2 X 4 R 40 ,
- X 4 is selected from the group consisting of O, S, S ⁇ O, and SO 2 ;
- each R 40 is independently C 10 -C 22 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl, C 1 -C 8 alkylene, or C 1 -C 8 heteroalkylene.
- Each heterocyclic and heteroaryl ring system is optionally substituted with C 1 -C 3 alkyl, —OH, amino and carboxyl groups.
- the present invention utilizes the following Y 1 groups: CH 2 , CHMe, CH(isopropyl), CH(tertiarybutyl), C(Me) 2 , C(Et) 2 , C(isopropyl) 2 , and C(propyl) 2 .
- the present invention utilizes the following X 2 groups:
- R is:
- X 3 is independently C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl;
- R 42 is independently hydrogen or C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl.
- Each heterocyclic is optionally substituted with one or more, preferably, 1-3, C 1 -C 3 alkyl, —OH, amino and/or carboxyl groups.
- R is:
- each X 3 is independently amino, hydroxyl, mercapto, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, C 1 -C 6 alkylthio, a bile acid based alkoxy group, a sugar moiety, a PEG moiety, and —O—CH 2 —CH(OR 40 )CH 2 X 4 R 40 ,
- X 4 is selected from the group consisting of O, S, S ⁇ O, and SO 2 ;
- each R 40 is independently C 10 -C 22 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, C 3 -C 9 heteroaryl, C 1 -C 8 alkylene, or C 1 -C 8 heteroalkylene; and
- R 42 is independently hydrogen or C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl.
- R 42 is independently hydrogen or C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl; and each X 3 independently is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino, or C 1 -C 6 alkylthio.
- R is represented by the following structures:
- R 43 is C 10 -C 22 alkyl or alkylene
- R 44 is H or C 1 -C 6 alkyl
- R 45 represents side chain alkyl groups present in naturally occurring alpha amino acids
- R is:
- R is —C(R 200 R 201 )O(R 202 R 203 )P(O)OR 204 NR 205 R 206 , wherein each R 200 , R 201 , R 202 , R 203 , R 204 R 205 and R 206 is independently H, a C 1 -C 8 alkyl, C 3 -C 9 heterocyclyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, C 3 -C 9 heteroaryl, wherein each alkyl, heterocyclyl, cycloalkyl, aryl, and heteroaryl is optionally substituted.
- R is —CH(R 201 )OCH 2 P(O)OR 204 NHR 206 , wherein R 201 is C 1 -C 8 alkyl, R 24 is phenyl, optionally substituted.
- R 206 is —CHR 207 C(O)OR 208 wherein R 207 is selected from the group consisting of the naturally occurring amino acid side chains and —CO 2 H esters thereof and R 208 is C 1 -C 8 alkyl.
- R 206 is C 1 -C 6 alkyl, optionally substituted with 1-3, CO 2 H, SH, NH 2 , C 6 -C 10 aryl, and C 2 -C 10 heteroaryl.
- R is:
- R is:
- Y 1 is —C(R 38 ) 2 , wherein each R 38 is independently hydrogen or C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl.
- PEG polyethylene glycol
- R is
- R 50 is —OH or hydrogen
- R 51 is —OH, or hydrogen
- W is —CH(CH 3 )W 1 ;
- W 1 is a substituted C 1 -C 8 alkyl group containing a moiety which is optionally negatively charged at physiological pH
- said moiety is selected from the group consisting of CO 2 H, SO 3 H, SO 2 H, —P(O)(OR 52 )(OH), —OP(O)(OR 52 )(OH), and OSO 3 H,
- R 52 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 9 heterocyclyl, C 6 -C 10 aryl, or C 3 -C 9 heteroaryl.
- Each heterocyclic and heteroaryl ring system is optionally substituted with one or more, preferably 1-3, C 1 -C 3 alkyl, —OH, amino and/or carboxyl groups.
- R is:
- R 53 is H or C 1 -C 6 alkyl.
- R is SO 3 H.
- R comprises a cleavable linker, wherein the term “cleavable linker” refers to a linker which has a short half life in vivo.
- the breakdown of the linker Z in a compound releases or generates the active compound.
- the cleavable linker has a half life of less than ten hours. In one embodiment, the cleavable linker has a half life of less than an hour. In one embodiment, the half life of the cleavable linker is between one and fifteen minutes.
- the cleavable linker has at least one connection with the structure: C*— C( ⁇ X*)X*—C* wherein C* is a substituted or unsubstituted methylene group, and X* is S or O.
- the cleavable linker has at least one C*—C( ⁇ O)O—C* connection.
- the cleavable linker has at least one C*—C( ⁇ O)S—C* connection.
- the cleavable linker has at least one —C( ⁇ O)N*—C*—SO 2 —N*-connection, wherein N* is —NH— or C 1 -C 6 alkylamino.
- the cleavable linker is hydrolyzed by an esterase enzyme.
- the linker is a self-immolating linker, such as that disclosed in U.S. patent publication 2002/0147138, to Firestone; PCT Appl. No. US05/08161 and PCT Pub. No. 2004/087075.
- the linker is a substrate for enzymes. See generally Rooseboom et al., 2004, Pharmacol. Rev. 56:53-102.
- composition comprising any of the compounds described herein, and at least a pharmaceutically acceptable excipient.
- this invention provides a composition comprising any of the compounds described herein, and a pharmaceutically acceptable excipient.
- compositions suitable for oral delivery can be formulated for different routes of administration.
- routes that may be used include transdermal, intravenous, intraarterial, pulmonary, rectal, nasal, vaginal, lingual, intramuscular, intraperitoneal, intracutaneous, intracranial, and subcutaneous routes.
- Suitable dosage forms for administering any of the compounds described herein include tablets, capsules, pills, powders, aerosols, suppositories, parenterals, and oral liquids, including suspensions, solutions and emulsions. Sustained release dosage forms may also be used, for example, in a transdermal patch form. All dosage forms may be prepared using methods that are standard in the art (see e.g., Remington's Pharmaceutical Sciences, 16 th ed., A. Oslo editor, Easton Pa. 1980).
- compositions in accordance with the invention are prepared by conventional means using methods known in the art.
- compositions disclosed herein may be used in conjunction with any of the vehicles and excipients commonly employed in pharmaceutical preparations, e.g., talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous solvents, oils, paraffin derivatives, glycols, etc. Coloring and flavoring agents may also be added to preparations, particularly to those for oral administration. Solutions can be prepared using water or physiologically compatible organic solvents such as ethanol, 1,2-propylene glycol, polyglycols, dimethylsulfoxide, fatty alcohols, triglycerides, partial esters of glycerin and the like.
- Solid pharmaceutical excipients include starch, cellulose, hydroxypropyl cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like.
- Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
- the compositions provided herein comprises one or more of ⁇ -tocopherol, gum arabic, and/or hydroxypropyl cellulose.
- this invention provides sustained release formulations such as drug depots or patches comprising an effective amount of a compound provided herein.
- the patch further comprises gum Arabic or hydroxypropyl cellulose separately or in combination, in the presence of alpha-tocopherol
- the hydroxypropyl cellulose has an average MW of from 10,000 to 100,000.
- the hydroxypropyl cellulose has an average MW of from 5,000 to 50,000.
- co-administration can be in any manner in which the pharmacological effects of both are manifest in the patient at the same time.
- co-administration does not require that a single pharmaceutical composition, the same dosage form, or even the same route of administration be used for administration of both the compound of this invention and the other agent or that the two agents be administered at precisely the same time.
- co-administration will be accomplished most conveniently by the same dosage form and the same route of administration, at substantially the same time. Obviously, such administration most advantageously proceeds by delivering both active ingredients simultaneously in a novel pharmaceutical composition in accordance with the present invention.
- a method for increasing tissue and/or cellular oxygenation comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.
- a method for increasing oxygen affinity of hemoglobin S in a subject comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.
- a method for treating a condition associated with oxygen deficiency comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.
- a method for treating oxygen deficiency associated with sickle cell anemia comprising administering to a subject in need thereof a therapeutically effective amount of any of the compounds or compositions described herein.
- a method for treating sickle cell disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of the compounds or compositions described herein.
- a method for treating cancer, a pulmonary disorder, stroke, high altitude sickness, an ulcer, a pressure sore, Alzheimer's disease, acute respiratory disease syndrome, and a wound comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of the compounds or compositions described herein.
- the reactions are preferably carried out in a suitable inert solvent that will be apparent to the skilled artisan upon reading this disclosure, for a sufficient period of time to ensure substantial completion of the reaction as observed by thin layer chromatography, 1 H-NMR, etc. If needed to speed up the reaction, the reaction mixture can be heated, as is well known to the skilled artisan.
- the final and the intermediate compounds are purified, if necessary, by various art known methods such as crystallization, precipitation, column chromatography, and the likes, as will be apparent to the skilled artisan upon reading this disclosure.
- a 5 and B 5 are independently NR 14 , O, S, S(O)x, NBoC, CH 2 , CHR 14 , C(R 14 ) 2 provided that when both A 5 and B 5 are present in a ring, both are not CH 2 , CHR 14 , C(R 14 ) 2 , and provided that if only a single A 5 or B 5 is present in a ring, that A 5 or B 5 is not CH 2 , CHR 14 , C(R 14 ) 2 ;
- R 14 is C 1 -C 6 alkyl, COR 15 or COOR 15 ; wherein R 15 is optionally substituted C 1 -C 6 alkyl, optionally substituted C 6 -C 10 aryl, optionally substituted 5-10 membered heteroaryl containing up to 5 ring heteroatoms, or optionally substituted 4-10 membered heterocycle containing up to 5 ring heteroatoms, wherein the heteroatom is selected from the group consisting of O, N, S, and oxidized forms of N and S;
- X, and X 5 each represents a leaving group and are independently selected from Cl, Br, and I.
- X 6 represents CR, N, O, S(O)x; wherein x is 0, 1, or 2;
- Y 5 represents a leaving group selected from Cl, F, Br, I, OSO 2 R 71 and OSO 2 Ar;
- R 71 is C 1 -C 6 alkyl
- Ar is phenyl optionally substituted with 1-3 halo and/or C 1 -C 4 alkyl groups
- n 0, 1, or 2.
- the ice cooling bath was allowed to expire over 90 min and the mixture was stirred at RT for 2-48 hours.
- the mixture was stirred for 10 min, then filtered through a pad of silica.
- the silica was washed with ethyl acetate 2-20 mL.
- the combined filtrates were evaporated and the residue was dried on highvac.
- the residue was purified by preparative HPLC or flash silica gel chromatography.
- a solution of aqueous 1N Na 2 CO 3 is then added to produce a solution of pH ⁇ 8, the mixture was extracted with DCM (3 ⁇ 10-50 mL), dried over sodium sulfate, and concentrated to the crude substituted methylene chloride (2a), which is then purified by column chromatography on silica gel (0-100% ethyl acetate-hexanes).
- the double bond of heterocyclohexene carboxylate 8 is reduced to give the cis-heterocyclohexane 11-cis carboxylate under palladium catalyzed hydrogenation conditions (Step 6).
- Reduction of the ester group of 11-cis by LAH or DIBAL yields cis-alcohol 12-OH-cis (Step 8).
- Conversion of the alcohol 12-OH-cis to its chloride, bromide or sulfonate (such as mesylate, tosylate) 13-X-cis can be achieved by reacting with thionyl chloride, or Ph 3 PBr 2 , or sufonyl chloride (such as mesyl chloride or tosyl chloride) (Step 9).
- the cis-cyclohexane carboxylate 11-cis can also be isomerized to the thermodynamically more stable trans-isomer 11-trans by the treatment with an alcoholic alkoxide (e.g., ethoxide) solution.
- transformation of 11-trans ester to 12-trans alcohol and 13-X-trans halide is accomplished by applying conditions of Step 8 and Step 9 similar to these for the corresponding cis-isomers.
- the ketone ester 14 is converted to the triflate intermediate 15 by treating with a triflating agent (e.g, triflic anhydride) in the presence of an organic base such as Hunig's base (Step 1).
- a triflating agent e.g, triflic anhydride
- an organic base such as Hunig's base
- Suzuki coupling of the triflate 15 with a boronic acid or ester affords heterocyclo carboxylate 16 (Step 2).
- Subsequent reduction of the ester group by LAH or DIBAL gives the corresponding alcohol 18 (Step 3).
- the double bond of 16 is reduced to give the saturated heterolic analog 17 under palladium catalyzed hydrogenation conditions (Step 5).
- Reduction of the ester group of 17 by LAH or DIBAL yields alcohol 20 (Step 7).
- Conversion of the alcohol 20 to its chloride, bromide or sulfonate (such as mesylate, tosylate) 21 can be achieved by reacting with thionyl chloride, or Ph 3 PBr 2 , or sufonyl chloride (such as mesyl chloride or tosyl chloride) (Step 8).
- Chiral pyrrolidine methylene derivatives 25 and 26 can be prepared according to reaction sequence depicted herein.
- the pyrrolidine ester 24 is produced via a 1,3-dipolar cycloaddition of alkene 22 with azomethine-ylide generated in situ from formaldehyde and amino acid 23 alkene (Step 1). Subsequent reduction of the ester to alcohol 24 and further conversion 25 are accomplished by analogous methods described herein. If a chiral auxiliary group such as chiral oxazolidinone derivative 22a is used, optically active pyrrolidine derivatives 25 and 26 can also be obtained. Coupling of 25 and 26 with hydroxyl(hetero)arylaldehyde derivatives (3a/3b) by general method A or B affords the corresponding aryloxy/heteroaryloxyether analogs (4).
- Protected amides of formula —CONHR 95 and —CONHOR 95 can be converted e.g., hydrolyzed to the corresponding amides according to methods known to the skilled artisan.
- Compounds of structure 4 can be synthesized via general synthetic scheme 1. Reduction of carboxylic acid derivative 1 gives hydroxymethyl analog 2, which can be N-derivativtized at via copper-mediated N-arylation reaction (CuI, Ar—I, base such as N,N-dimethylethylenediamine and potassium phosphate, heat) to give key hydroxymethyl intermediate 3. Coupling of 3 with phenol aldehyde 4 produces the desired aldehyde analog 5 via typical Mistunobu conditions using either triphenylphosphine or polymer supported triphenylphosphine.
- a 1 is a heteroatom or a hydrocarbyl moiety as defined herein.
- the carboxylate 1a (1-10 mmol) is first dissolved in DMF (2-20 mL); to this was then added a base such as NaH or Cs 2 CO 3 (1-1.2 eq), followed by the addition of alkyl halide (eg, BnBr) (0.9-1.5 eq).
- alkyl halide eg, BnBr
- Compounds of structure 5 can be synthesized via general synthetic scheme 1. Reduction of carboxylic acid derivative 1 gives hydroxymethyl analog 2, which can be N-alkylated by simple alkyl halide (base, R 1 X, heat) or aryl halide (ArX) via copper-mediated N-arylation reaction (CuI, Ar—I, base such as N,N-dimethylethylenediamine and potassium phosphate, heat) to give key hydroxymethyl intermediate 3. Coupling of 3 with phenol aldehyde 4 produces the desired aldehyde analog 5 via typical Mistunobu conditions using either triphenylphosphine or polymer supported triphenylphosphine.
- a 1 is a heteroatom or a hydrocarbyl moiety as defined herein.
- the carboxylate 1 can be first alkylated and then reduced to give N-alkyl hydroxymethylene analog 3.
- the carboxylate 1 (1-10 mmol) is first dissolved in DMF (2-20 mL); to this was then added a base such as NaH or Cs 2 CO 3 (1-1.2 eq), followed by the addition of alkyl halide (eg, BnBr) (0.9-1.5 eq).
- alkyl halide eg, BnBr
- workup A water was added to the reaction mixture, the precipitated product was collected, washed with water, and then subjected to preparative HPLC or flash silica gel chromatography purification.
- Syntheses of the ester prodrugs start with the free carboxylic acid bearing the tertiary amine.
- the free acid is activated for ester formation in an aprotic solvent and then reacted with a free alcohol group in the presence of an inert base, such as triethyl amine, to provide the ester prodrug.
- Activating conditions for the carboxylic acid include forming the acid chloride using oxalyl chloride or thionyl chloride in an aprotic solvent, optionally with a catalytic amount of dimethyl formamide, followed by evaporation.
- aprotic solvents include, but are not limited to methylene chloride, tetrahydrofuran, and the like.
- activations can be performed in situ by using reagents such as BOP (benzotriazol-I-yloxytris(dimethylamino)phosphonium hexafluorophosphate, and the like (see Nagy et al., 1993, Proc. Natl. Acad. Sci. USA 90:6373-6376) followed by reaction with the free alcohol.
- BOP benzotriazol-I-yloxytris(dimethylamino)phosphonium hexafluorophosphate
- Isolation of the ester products can be affected by extraction with an organic solvent, such as ethyl acetate or methylene chloride, against a mildly acidic aqueous solution; followed by base treatment of the acidic aqueous phase so as to render it basic; followed by extraction with an organic solvent, for example ethyl acetate or methylene chroride; evaporation of the organic solvent layer; and recrystalization from a solvent, such as ethanol.
- the solvent can be acidified with an acid, such as HCl or acetic acid to provide a pharmaceutically acceptable salt thereof.
- the crude reaction can be passed over an ion exchange column bearing sulfonic acid groups in the protonated form, washed with deionized water, and eluted with aqueous ammonia; followed by evaporation.
- Suitable free acids bearing the tertiary amine are commercially available, such as 2-(N-morpholino)-propionic acid, N,N-dimethyl-beta-alanine, and the like. Non-commercial acids can be synthesized in straightforward manner via standard literature procedures.
- Carbonate and carbamate prodrugs can be prepared in an analogous way.
- amino alcohols and diamines can be activated using activating agents such as phosgene or carbonyl diimidazole, to provide an activated carbonates, which in turn can react with the alcohol and/or the phenolic hydroxy group on the compounds utilized herein to provide carbonate and carbamate prodrugs.
- the mixture was then stirred at ⁇ 40° C. for 1 h, quenched with a mixture of HCl (12 N, 12 mL) and THF (28 mL), warmed to RT, and added water (20 mL). The pH of the mixture was adjusted to pH 8-9 with solid K 2 CO 3 . The aqueous layer was extracted with EtOAc (30 mL) twice.
- GBT915 (S)-2-((1-benzoylpyrrolidin-2-yl)methoxy)-6-hydroxybenzaldehyde
- Step 1 To a solution of (S)-pyrrolidin-2-ylmethanol (700 mg, 6.92 mmol) and DIPEA (1.20 mL, 6.92 mmol) in DCM (12 ml) at 0° C. was added benzoyl chloride (0.80 mL, 6.92 mmol), 30 min later it was diluted with more DCM and was washed with Sat. NaHCO 3 , brine, dried over MgSO 4 , concentrated to give crude product, which was purified by column (EtOAc 0-100%) to give (S)-(2-(hydroxymethyl)pyrrolidin-1-yl)(phenyl)methanone (1.2 g).
- GBT952 (S)-2-((1-benzoylpiperidin-2-yl)methoxy)-6-hydroxybenzaldehyde
- Step 2 To a solution of 2,6-dihydroxybenzaldehyde (110 mg, 0.80 mmol) and (S)-(2-(hydroxymethyl)piperidin-1-yl)(phenyl)methanone (0.23 g, 1.04 mmol) in THF (1.5 mL) was added PPh 3 (310 mg, 1.20 mmol) and DIAD (0.23 ml, 1.20 mmol) at 0° C., then it was warmed up to room temperature and stirred for 1 h.
- PPh 3 310 mg, 1.20 mmol
- DIAD 0.23 ml, 1.20 mmol
- GBT961 (S)-2-hydroxy-6-((1-nicotinoylpyrrolidin-2-yl)methoxy)benzaldehyde
- Step 2 To a solution of (S)-(2-(hydroxymethyl)pyrrolidin-1-yl)(pyridin-3-yl)methanone (150 mg, 0.73 mmol) and 2,6-dihydroxybenzaldehyde (0.13 g, 0.91 mmol) in THF (1.5 ml) was added PPh 3 (0.29 g, 1.1 mmol) and DIAD (0.21 ml, 1.1 mmol) at 0° C.
- GBT962 (S)-2-hydroxy-6-((1-isonicotinoylpyrrolidin-2-yl)methoxy)benzaldehyde
- Step 2 To a solution of (S)-(2-(hydroxymethyl)pyrrolidin-1-yl)(pyridin-3-yl)methanone (150 mg, 0.73 mmol) and 2,6-dihydroxybenzaldehyde (0.13 g, 0.91 mmol) in THF (1.5 mL) was added PPh 3 (0.29 g, 1.1 mmol) and DIAD (0.21 mL, 1.1 mmol) at 0° C.
- Step 2 To a solution of (S)-(2-(hydroxymethyl)pyrrolidin-1-yl)(pyridin-2-yl)methanone (100 mg, 0.48 mmol) and 2,6-dihydroxybenzaldehyde (0.08 g, 0.6 mmol) in THF (5 mL) was added PPh 3 (polymer supported, 600 mg, 0.72 mmol) and DIAD (0.15 mL, 0.72 mmol) at room temperature.
- PPh 3 polymer supported, 600 mg, 0.72 mmol
- DIAD 0.15 mL, 0.72 mmol
- GBT1064 (S)-2-hydroxy-6-((1-(1-isopropyl-1H-pyrazole-5-carbonyl)pyrrolidin-2-yl)methoxy)benzaldehyde
- Step 1 To a solution of (S)-pyrrolidin-2-ylmethanol (100 mg, 1 mmol) and 1-isopropyl-1H-pyrazole-5-carboxylic acid (0.15 g, 1 mmol) in DMF (2 mL) was added HATU (0.38 g, 1 mmol) and then the mixture was stirred until finished, it was diluted with water and extracted with EtOAc, organic layer was dried and concentrated to give crude product, which was purified by column (100% EtOAc) to give (S)-(2-(hydroxymethyl)pyrrolidin-1-yl)(1-isopropyl-1H-pyrazol-5-yl)methanone (120 mg).
- Step 2 To a solution of (S)-(2-(hydroxymethyl)pyrrolidin-1-yl)(1-isopropyl-1H-pyrazol-5-yl)methanone (120 mg, 0.51 mmol) and 2,6-dihydroxybenzaldehyde (0.09 g, 0.66 mmol) in THF (4 ml) was added PPh 3 (Polymer supported, 640 mg, 0.77 mmol) and DIAD (0.16 mL, 0.77 mmol) at 0° C.
- PPh 3 Polymer supported, 640 mg, 0.77 mmol
- DIAD 0.16 mL, 0.77 mmol
- GBT1118 (S)-2-hydroxy-6-((1-nicotinoylpiperidin-2-yl)methoxy)benzaldehyde
- Step 1&2 To a solid sample of (S)-tert-butyl 2-(hydroxymethyl)piperidine-1-carboxylate (215 mg, 1.02 mmol) was added 4N HCl in dioxane (1 mL). After stirred for 30 min, it was concentrated to give (S)-piperidin-2-ylmethanol HCl salt. To a suspension of (S)-piperidin-2-ylmethanol HCl salt in DCM (3 mL) at 0° C. was added DIPEA (0.39 mL, 2.24 mmol) and nicotinyl chloride (0.2 g, 1.12 mmol).
- Step 2 To a solution of (S)-(2-(hydroxymethyl)piperidin-1-yl)(pyridin-3-yl)methanone (130 mg, 0.59 mmol) and 2,6-dihydroxybenzaldehyde (0.11 g, 0.77 mmol) in THF (4 mL) was added PPh 3 (polymer supported, 0.74 g, 0.89 mmol) and DIAD (0.17 mL, 0.89 mmol) at 0° C.
- GBT1579 (S)-2-hydroxy-6-((1-(6-methylnicotinoyl)piperidin-2-yl)methoxy)benzaldehyde
- Steps 1&2 To a suspension of 6-methylnicotinic acid (270 mg, 2 mmol) in DCM (5 mL) was added oxalyl chloride (0.34 mL, 4 mmol) at 0° C. followed by a drop of DMF, after stirred for 2 hour at room temperature, the solution was concentrated to give crude acid chloride.
- Step 3 To a solution of (S)-(2-(hydroxymethyl)piperidin-1-yl)(6-methylpyridin-3-yl)methanone (100 mg, 0.43 mmol) and 2,6-dihydroxybenzaldehyde (80 mg, 0.56 mmol) in THF (2.5 mL) at 0° C.
- GBT1580 (S)-2-hydroxy-6-((1-(2-methylnicotinoyl)piperidin-2-yl)methoxy)benzaldehyde
- Step 1&2 To a suspension of 2-methylnicotinic acid (300 mg, 2.19 mmol) in DCM (5 mL) was added oxalyl chloride (0.28 mL, 3.3 mmol) at 0° C. and was further stirred for 2 hour at room temperature, then the solution was concentrated to give crude acid chloride.
- Step 3 To a solution of (S)-(2-(hydroxymethyl)piperidin-1-yl)(2-methylpyridin-3-yl)methanone (180 mg, 0.77 mmol) and 2,6-dihydroxybenzaldehyde (140 mg, 1.0 mmol) in THF (5 mL) at 0° C.
- GBT1124 (S)-2-((4-benzoylmorpholin-3-yl)methoxy)-6-hydroxybenzaldehyde
- Step 1&2 To a solid sample of (R)-tert-butyl 3-(hydroxymethyl)morpholine-4-carboxylate (150 mg, 0.69 mmol) was added 4N HCl in dioxane (1.5 mL). After stirred for 30 min, it was concentrated to give (R)-(3-(hydroxymethyl)morpholino)(phenyl)methanone as HCl salt. To a suspension of (R)-(3-(hydroxymethyl)morpholino)(phenyl)methanone HCl salt in DCM (2 mL) at 0° C. was added DIPEA (0.36 mL, 2.07 mmol) and benzoyl chloride (0.08 mL, 0.69 mmol).
- GBT1126 (S)-2-hydroxy-6-((1-(phenylsulfonyl)pyrrolidin-2-yl)methoxy)benzaldehyde
- Step 1 To a solution of (S)-pyrrolidin-2-ylmethanol (500 mg, 4.94 mmol) in DCM (10 mL) at 0° C. was added TEA (1.04 mL, 7.41 mmol) followed by benzenesulfonyl chloride (0.63 mL, 4.94 mmol). After stirred for 30 min, it was diluted with DCM, washed with aqueous Sat. NaHCO3, brine, dried and concentrated to give crude product, which was purified by column to (S)-(1-(phenylsulfonyl)pyrrolidin-2-yl)methanol.
- Step 2 To a solution of (S)-(1-(phenylsulfonyl)pyrrolidin-2-yl)methanol (125 mg, 0.54 mmol) and 2,6-dihydroxybenzaldehyde (0.1 g, 0.7 mmol) in THF (2 mL) was added PPh 3 (0.21 g, 0.81 mmol) and DIAD (0.16 mL, 0.81 mmol) at 0° C.
- GBT1128 (S)-2-hydroxy-6-((1-(pyridin-3-ylsulfonyl)pyrrolidin-2-yl)methoxy)benzaldehyde
- Step 1 To a solution of (S)-pyrrolidin-2-ylmethanol (320 mg, 3.16 mmol) in DCM (6 mL) at 0° C. was added TEA (0.97 mL, 6.95 mmol) followed by pyridine-3-sulfonyl chloride (0.68 g, 3.16 mmol). After stirred for 30 min. it was diluted with DCM, washed with aqueous Sat. NaHCO3, brine, dried and concentrated to give crude product, which was purified by column to give (S)-(1-(pyridin-3-ylsulfonyl)pyrrolidin-2-yl)methanol (66 mg).
- Step 2 To a solution of (S)-(1-(pyridin-3-ylsulfonyl)pyrrolidin-2-yl)methanol (65 mg, 0.29 mmol) and 2,6-dihydroxybenzaldehyde (0.06 g, 0.41 mmol) in THF (2 mL) was added PPh 3 (polymer supported, 0.37 g, 0.44 mmol) and DIAD (0.09 mL, 0.44 mmol) at 0° C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/776,726 US20160083343A1 (en) | 2013-03-15 | 2014-03-10 | Compounds and uses thereof for the modulation of hemoglobin |
US16/186,275 US11053195B2 (en) | 2013-03-15 | 2018-11-09 | Compounds and uses thereof for the modulation of hemoglobin |
US16/446,331 US10450269B1 (en) | 2013-11-18 | 2019-06-19 | Compounds and uses thereof for the modulation of hemoglobin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/815,735 US8952171B2 (en) | 2013-03-15 | 2013-03-15 | Compounds and uses thereof for the modulation of hemoglobin |
US201361905803P | 2013-11-18 | 2013-11-18 | |
PCT/US2014/022769 WO2014150268A1 (en) | 2013-03-15 | 2014-03-10 | Compounds and uses thereof for the modulation of hemoglobin |
US14/776,726 US20160083343A1 (en) | 2013-03-15 | 2014-03-10 | Compounds and uses thereof for the modulation of hemoglobin |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/815,735 Continuation US8952171B2 (en) | 2013-03-15 | 2013-03-15 | Compounds and uses thereof for the modulation of hemoglobin |
US13/815,735 Continuation-In-Part US8952171B2 (en) | 2013-03-15 | 2013-03-15 | Compounds and uses thereof for the modulation of hemoglobin |
PCT/US2014/022769 A-371-Of-International WO2014150268A1 (en) | 2013-03-15 | 2014-03-10 | Compounds and uses thereof for the modulation of hemoglobin |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/127,776 Continuation US20190010121A1 (en) | 2013-03-15 | 2018-09-11 | Compounds and uses thereof for the modulation of hemoblogin |
US16/186,275 Continuation US11053195B2 (en) | 2013-03-15 | 2018-11-09 | Compounds and uses thereof for the modulation of hemoglobin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160083343A1 true US20160083343A1 (en) | 2016-03-24 |
Family
ID=51580732
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/776,726 Abandoned US20160083343A1 (en) | 2013-03-15 | 2014-03-10 | Compounds and uses thereof for the modulation of hemoglobin |
US16/127,776 Abandoned US20190010121A1 (en) | 2013-03-15 | 2018-09-11 | Compounds and uses thereof for the modulation of hemoblogin |
US16/186,275 Active US11053195B2 (en) | 2013-03-15 | 2018-11-09 | Compounds and uses thereof for the modulation of hemoglobin |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/127,776 Abandoned US20190010121A1 (en) | 2013-03-15 | 2018-09-11 | Compounds and uses thereof for the modulation of hemoblogin |
US16/186,275 Active US11053195B2 (en) | 2013-03-15 | 2018-11-09 | Compounds and uses thereof for the modulation of hemoglobin |
Country Status (22)
Country | Link |
---|---|
US (3) | US20160083343A1 (zh) |
EP (1) | EP2970196B1 (zh) |
JP (3) | JP6426694B2 (zh) |
KR (1) | KR102280614B1 (zh) |
CN (2) | CN105073728A (zh) |
AP (1) | AP2015008721A0 (zh) |
AU (3) | AU2014237340C1 (zh) |
BR (1) | BR112015021985B1 (zh) |
CA (1) | CA2903220C (zh) |
CL (1) | CL2015002501A1 (zh) |
EA (1) | EA034922B1 (zh) |
ES (1) | ES2852054T3 (zh) |
IL (1) | IL241060B (zh) |
MX (1) | MX2015011445A (zh) |
MY (1) | MY191087A (zh) |
PE (1) | PE20161035A1 (zh) |
SA (2) | SA517382253B1 (zh) |
SG (2) | SG11201507320QA (zh) |
TW (1) | TWI695830B (zh) |
UY (1) | UY35426A (zh) |
WO (1) | WO2014150268A1 (zh) |
ZA (1) | ZA201703791B (zh) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9981939B2 (en) | 2013-03-15 | 2018-05-29 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10004725B2 (en) | 2015-03-30 | 2018-06-26 | Global Blood Therapeutics, Inc. | Methods of treatment |
US10017491B2 (en) | 2013-03-15 | 2018-07-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10034879B2 (en) | 2011-12-28 | 2018-07-31 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
US10077249B2 (en) | 2016-05-12 | 2018-09-18 | Global Blood Therapeutics, Inc. | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde |
US10100040B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US10137118B2 (en) | 2014-02-07 | 2018-11-27 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10315991B2 (en) | 2013-03-15 | 2019-06-11 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10377741B2 (en) | 2011-12-28 | 2019-08-13 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
US10450269B1 (en) | 2013-11-18 | 2019-10-22 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10493035B2 (en) | 2016-10-12 | 2019-12-03 | Global Blood Therapeutics, Inc. | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
US10683285B2 (en) | 2018-11-19 | 2020-06-16 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
US11014908B2 (en) | 2018-11-29 | 2021-05-25 | Pfizer Inc. | Chemical compounds |
US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
US11053195B2 (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US11236109B2 (en) | 2013-03-15 | 2022-02-01 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016043849A2 (en) * | 2014-07-24 | 2016-03-24 | Global Blood Therapeutics, Inc. | Compounds for treating acute respiratory distress syndrome or a negative effect thereof |
BR112022019423A2 (pt) | 2020-03-31 | 2022-12-06 | Global Blood Therapeutics Inc | Moduladores de hemoglobina |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160083348A1 (en) * | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
Family Cites Families (434)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE276479C (zh) | ||||
DE226590C (zh) | ||||
DE258226C (zh) | ||||
NL103316C (zh) | 1956-02-13 | 1900-01-01 | ||
BE787576A (fr) | 1971-08-13 | 1973-02-14 | Hoechst Ag | Derives de benzofuranne et leur utilisation comme azureurs optiques |
BE787580A (fr) | 1971-08-13 | 1973-02-14 | Hoechst Ag | Procede de preparation de derives du furanne |
GB1409865A (en) | 1973-02-13 | 1975-10-15 | Science Union & Cie | Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them |
US4062858A (en) | 1976-12-22 | 1977-12-13 | E. R. Squibb & Sons, Inc. | Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-b]pyrazolo[4,3-e]pyridin-11(1H)-ones and 11(1H)-imines |
GB1593417A (en) | 1976-12-22 | 1981-07-15 | Squibb & Sons Inc | Carbocyclic-fused pyrazolopyridine derivatives |
EP0010063B1 (de) | 1978-10-04 | 1982-12-29 | Ciba-Geigy Ag | Verfahren zur Herstellung von Furanyl-benzazolen |
DE2853765A1 (de) | 1978-12-13 | 1980-06-26 | Bayer Ag | Verfahren zur herstellung von benzimidazolylbenzofuranen |
DE2904829A1 (de) | 1979-02-08 | 1980-08-14 | Bayer Ag | Verfahren zur herstellung von benzimidazolylbenzofuran |
EP0022229B1 (en) | 1979-06-29 | 1982-12-08 | The Wellcome Foundation Limited | Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof |
IT1193786B (it) * | 1980-12-18 | 1988-08-24 | Wellcome Found | Composti eterei dotati di attivita' mitigatrice delle emoglobinopatie intermedi e procedimento per la loro preparazione |
JPS5929667A (ja) | 1982-08-13 | 1984-02-16 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体および強心剤 |
US4478834A (en) | 1983-02-11 | 1984-10-23 | Usv Pharmaceutical Corporation | Dihydropyridines and their use in the treatment of asthma |
GB8402740D0 (en) | 1984-02-02 | 1984-03-07 | Scras | Furo-(3 4-c)-pyridine derivatives |
JPS6140236A (ja) | 1984-08-02 | 1986-02-26 | Yamanouchi Pharmaceut Co Ltd | ハイドロキノン誘導体 |
DE3431004A1 (de) | 1984-08-23 | 1986-03-06 | Hoechst Ag, 6230 Frankfurt | Neue 3-pyridylverbindungen und verfahren zu ihrer herstellung |
GB8603475D0 (en) | 1986-02-12 | 1986-03-19 | Glaxo Group Ltd | Chemical compounds |
DK111387A (da) | 1986-03-05 | 1987-09-06 | Otsuka Pharma Co Ltd | Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne |
US4831041A (en) | 1986-11-26 | 1989-05-16 | Fujisawa Pharmaceutical Co., Ltd. | Imidazopyridine compounds and processes for preparation thereof |
EP0278686A1 (en) | 1987-02-07 | 1988-08-17 | The Wellcome Foundation Limited | Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof |
JPH07121937B2 (ja) | 1987-03-18 | 1995-12-25 | 大塚製薬株式会社 | カルボスチリル誘導体 |
JPS63258463A (ja) * | 1987-04-14 | 1988-10-25 | Kumiai Chem Ind Co Ltd | 2−フエノキシピリミジン誘導体及び除草剤 |
GB8711802D0 (en) | 1987-05-19 | 1987-06-24 | Fujisawa Pharmaceutical Co | Dithioacetal compounds |
GB8718940D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
US4920131A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
JP2650038B2 (ja) | 1988-01-27 | 1997-09-03 | サントリー株式会社 | ピロリチジン化合物およびその用途 |
EP0336369A1 (en) | 1988-04-04 | 1989-10-11 | E.R. Squibb & Sons, Inc. | 3-Acylamino-1-[[[(substituted sulfonyl)amino]carbonyl]amino]2-azetidinones |
US4952574A (en) | 1988-09-26 | 1990-08-28 | Riker Laboratories, Inc. | Antiarrhythmic substituted N-(2-piperidylmethyl)benzamides |
IE81170B1 (en) | 1988-10-21 | 2000-05-31 | Zeneca Ltd | Pyridine derivatives |
US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
IT1230859B (it) | 1989-06-05 | 1991-11-08 | Corvi Camillo Spa | 2 alchinilfenoli sostituiti ad azione anti infiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
WO1991009594A1 (en) | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
EP0453210A3 (en) | 1990-04-19 | 1993-01-13 | Imperial Chemical Industries Plc | Pyridine derivatives |
IE912064A1 (en) | 1990-06-18 | 1991-12-18 | Merck & Co Inc | Inhibitors of hiv reverse transcriptase |
CA2051705A1 (en) | 1990-06-19 | 1991-12-20 | Kiyoaki Katano | Pyridine derivatives having angiotensin ii antagonism |
NL9001752A (nl) | 1990-08-02 | 1992-03-02 | Cedona Pharm Bv | Nieuwe 1,4-dihydropyridinederivaten. |
IL99731A0 (en) | 1990-10-18 | 1992-08-18 | Merck & Co Inc | Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them |
US5403816A (en) | 1990-10-25 | 1995-04-04 | Kumiai Chemical Industry Co., Ltd. | Picolinic acid derivative and herbicidal composition |
JPH05301872A (ja) | 1992-04-23 | 1993-11-16 | Kumiai Chem Ind Co Ltd | ピコリン酸誘導体及び除草剤 |
EP0498380A1 (de) | 1991-02-08 | 1992-08-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Komplexbildner |
JPH0641118A (ja) | 1991-05-31 | 1994-02-15 | Kumiai Chem Ind Co Ltd | ピコリン酸誘導体及び除草剤 |
US5185251A (en) | 1991-06-07 | 1993-02-09 | Merck & Co., Inc. | Microbial transformation of a substituted pyridinone using actinoplanacete sp. MA 6559 |
EP0591426A4 (en) | 1991-06-27 | 1996-08-21 | Univ Virginia Commonwealth | Sigma receptor ligands and the use thereof |
JP2600644B2 (ja) | 1991-08-16 | 1997-04-16 | 藤沢薬品工業株式会社 | チアゾリルベンゾフラン誘導体 |
FR2680512B1 (fr) | 1991-08-20 | 1995-01-20 | Adir | Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
US5202243A (en) | 1991-10-04 | 1993-04-13 | Merck & Co., Inc. | Method of hydroxylating 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone by incubation with liver slices |
GB9203798D0 (en) | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
EP0648209A1 (de) | 1992-07-01 | 1995-04-19 | Byk Gulden Lomberg Chemische Fabrik GmbH | Kontrastmittel für die mr diagnostik |
US5290941A (en) | 1992-10-14 | 1994-03-01 | Merck & Co., Inc. | Facile condensation of methylbenzoxazoles with aromatic aldehydes |
AU668818B2 (en) | 1993-04-07 | 1996-05-16 | Taiho Pharmaceutical Co., Ltd. | Thiazolidine derivative and pharmaceutical composition containing the same |
DE4318550A1 (de) | 1993-06-04 | 1994-12-08 | Boehringer Mannheim Gmbh | Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
US5534529A (en) | 1993-06-30 | 1996-07-09 | Sankyo Company, Limited | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses |
JPH0725882A (ja) | 1993-07-07 | 1995-01-27 | Res Dev Corp Of Japan | アクロメリン酸bおよびeを製造するための中間体と、その製造方法 |
EP0637586B1 (en) | 1993-08-05 | 1999-06-02 | HOECHST MARION ROUSSEL, Inc. | 2-(Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)-benzofuran-7-carbamate derivatives, their preparation and their use as acetylcholinesterase inhibitors |
EP0640609A1 (en) | 1993-08-24 | 1995-03-01 | Ono Pharmaceutical Co., Ltd. | Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species |
US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5840900A (en) | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
AU7992594A (en) | 1993-11-19 | 1995-06-06 | Ciba-Geigy Ag | Benzothiophene derivatives possessing a methoxyimino substituent as microbicides |
EP0658559A1 (de) * | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
EP0750631B1 (en) | 1994-02-14 | 2000-04-05 | Merrell Pharmaceuticals Inc. | Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace |
TW474813B (en) * | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
GB9420557D0 (en) | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
DE4442050A1 (de) | 1994-11-25 | 1996-05-30 | Hoechst Ag | Heterospiroverbindungen und ihre Verwendung als Elektrolumineszenzmaterialien |
US5650408A (en) | 1995-06-07 | 1997-07-22 | Karanewsky; Donald S. | Thiazolo benzazepine containing dual action inhibitors |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
CA2238081A1 (en) | 1995-11-22 | 1997-05-29 | S. Jane Desolms | Inhibitors of farnesyl-protein transferase |
GB9604311D0 (en) | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
JP3895404B2 (ja) | 1996-05-17 | 2007-03-22 | 興和株式会社 | カルコン誘導体及びこれを含有する医薬 |
CN1221417A (zh) | 1996-07-26 | 1999-06-30 | 雷迪博士研究基金会 | 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物 |
US6630496B1 (en) | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
JP2000516958A (ja) | 1996-08-26 | 2000-12-19 | ジェネティックス・インスチチュート・インコーポレーテッド | ホスホリパーゼ酵素の阻害剤 |
AU4136197A (en) | 1996-09-09 | 1998-03-26 | Kyowa Hakko Kogyo Co. Ltd. | Pyrrolocarbazole derivatives |
JP2001503762A (ja) | 1996-11-12 | 2001-03-21 | ノバルティス アクチェンゲゼルシャフト | 除草剤として有用なピラゾール誘導体 |
US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5932590A (en) | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6043389A (en) | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
FR2761069A1 (fr) | 1997-03-20 | 1998-09-25 | Pf Medicament | Spiroamines derivees de dihydrobenzofuranes, leur preparation et leur application comme medicaments |
FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
US5760232A (en) | 1997-06-16 | 1998-06-02 | Schering Corporation | Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds |
US6214817B1 (en) | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
US6011042A (en) | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
CA2306312A1 (en) | 1997-10-17 | 1999-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6103723A (en) | 1997-10-17 | 2000-08-15 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6111107A (en) | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
AU1722999A (en) | 1997-12-12 | 1999-07-05 | Euro-Celtique S.A. | Preparation of 3-substituted adenines and imidazo pyridines |
CA2322163A1 (en) | 1998-02-25 | 1999-09-02 | John Mckew | Inhibitors of phospholipase a2 |
CA2319493A1 (en) | 1998-03-18 | 1999-09-23 | Regine Bohacek | Heterocyclic signal transduction inhibitors, compositions containing them |
US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
RU2230740C2 (ru) | 1998-03-31 | 2004-06-20 | Акадиа Фармасьютикалз, Инк. | Производные азотсодержащих гетероциклических соединений и фармацевтическая композиция на их основе |
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
GB9810860D0 (en) | 1998-05-20 | 1998-07-22 | Hoechst Schering Agrevo Gmbh | Substituted pyridine and pyrimidines, processes for their preparation and their use as pesticides |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
IL139811A0 (en) | 1998-06-04 | 2002-02-10 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
GB9818627D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
RU2198871C1 (ru) | 1998-12-14 | 2003-02-20 | Ф.Хоффманн-Ля Рош Аг | Фенилглициновые производные |
US6544980B2 (en) | 1998-12-31 | 2003-04-08 | Aventis Pharmaceuticals Inc. | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
WO2000040564A1 (en) | 1998-12-31 | 2000-07-13 | Aventis Pharmaceuticals Inc. | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase |
WO2000046203A2 (en) | 1999-02-04 | 2000-08-10 | Millennium Pharmaceuticals, Inc. | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
EP1165515A1 (de) | 1999-03-31 | 2002-01-02 | Basf Aktiengesellschaft | Pyridin-2,3-dicarbonsäurediamide |
JP2000302757A (ja) | 1999-04-16 | 2000-10-31 | Shiseido Co Ltd | N−置換ピペリジン誘導体 |
US6251927B1 (en) | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
CZ20013834A3 (cs) | 1999-04-28 | 2002-04-17 | Aventis Pharma Deutschland Gmbh | Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují |
JP2002544242A (ja) | 1999-05-14 | 2002-12-24 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 酵素活性化抗腫瘍プロドラッグ化合物 |
US6184228B1 (en) | 1999-05-25 | 2001-02-06 | Anadys Pharmaceuticals, Inc. | Anti-sickling agents: selection methods and effective compounds |
EP1181296A1 (en) | 1999-06-03 | 2002-02-27 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
TR200103806T2 (tr) | 1999-06-28 | 2002-06-21 | Janssen Pharmaceutica N. V. | Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler. |
ATE312100T1 (de) | 1999-09-28 | 2005-12-15 | Eisai Co Ltd | Chinuclidin-verbindungen und medikamente die diese als aktive wirkstoffe enthalten |
SE9903759D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | Pharmaceutically active compounds |
ATE427925T1 (de) | 1999-11-05 | 2009-04-15 | Emisphere Tech Inc | Phenoxycarbonsaureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe |
AUPQ407699A0 (en) | 1999-11-16 | 1999-12-09 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
CZ20022332A3 (cs) | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
AU2001230537A1 (en) | 2000-02-01 | 2001-08-14 | Daiichi Pharmaceutical Co., Ltd. | Pyridoxazine derivatives |
FR2804431A1 (fr) | 2000-02-02 | 2001-08-03 | Adir | Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6506755B2 (en) | 2000-02-03 | 2003-01-14 | Hoffmann-La Roche Inc. | Thiazolidinecarboxyl acids |
AUPQ585000A0 (en) | 2000-02-28 | 2000-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
US6559140B2 (en) | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
KR20020081424A (ko) | 2000-03-09 | 2002-10-26 | 아벤티스 파마 도이칠란트 게엠베하 | Ppar 매개인자의 치료학적 용도 |
EP1265840A2 (en) | 2000-03-17 | 2002-12-18 | Corixa Corporation | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
KR100501608B1 (ko) | 2000-07-14 | 2005-07-18 | 에프. 호프만-라 로슈 아게 | 4-페닐-피리딘 유도체의 nk1 수용체의 길항성선구약물로서의 n-산화물 |
WO2002009723A2 (en) | 2000-08-01 | 2002-02-07 | Gmp Companies, Inc. | Ammonium salts of hemoglobin allosteric effectors, and uses thereof |
ES2261454T3 (es) | 2000-08-08 | 2006-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Compuestos biciclicos como ligandos del receptor h3. |
US6653313B2 (en) | 2000-08-10 | 2003-11-25 | Warner-Lambert Company Llc | 1,4-dihydropyridine compounds as bradykinin antagonists |
JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
AUPR034000A0 (en) | 2000-09-25 | 2000-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
IL155702A0 (en) | 2000-11-20 | 2003-11-23 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
JPWO2002051849A1 (ja) | 2000-12-26 | 2004-04-22 | 第一製薬株式会社 | Cdk4活性阻害剤 |
CA2433573A1 (en) | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Alkanoic acid derivatives, process for their production and use thereof |
WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
SE0100326D0 (sv) | 2001-02-02 | 2001-02-02 | Astrazeneca Ab | New compounds |
US20030022923A1 (en) | 2001-03-01 | 2003-01-30 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
SE0101324D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New process |
US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
JP4425628B2 (ja) | 2001-07-23 | 2010-03-03 | ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド | 細胞保護化合物、薬学的処方物および美容用処方物、ならびに方法 |
JP2003075970A (ja) | 2001-08-31 | 2003-03-12 | Konica Corp | ハロゲン化銀カラー写真感光材料、カラー写真感光材料、その画像形成方法及びデジタル画像情報作製方法 |
KR100467313B1 (ko) | 2001-11-22 | 2005-01-24 | 한국전자통신연구원 | 적색 유기 전기발광 화합물 및 그 제조 방법과 전기발광소자 |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
MXPA04005864A (es) | 2001-12-19 | 2004-10-29 | Atherogenics Inc | Derivados de charcona y su uso para tratar enfermedades. |
US20030190333A1 (en) | 2002-02-04 | 2003-10-09 | Corixa Corporation | Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins |
JP4606027B2 (ja) | 2002-04-03 | 2011-01-05 | トポターゲット ユーケー リミテッド | Hdac阻害剤としてのピペラジン結合を有するカルバミン酸化合物 |
WO2003088980A1 (en) | 2002-04-18 | 2003-10-30 | Embury Stephen H | Method and composition for preventing pain in sickle cell patients |
US6608076B1 (en) | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
WO2004014899A1 (en) * | 2002-08-08 | 2004-02-19 | Smithkline Beecham Corporation | Thiophene compounds |
EP1581525A2 (en) | 2002-08-09 | 2005-10-05 | AstraZeneca AB | Compounds having an activity at metabotropic glutamate receptors |
EP1536790A2 (en) | 2002-08-09 | 2005-06-08 | AstraZeneca AB | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
JPWO2004018430A1 (ja) | 2002-08-23 | 2005-12-08 | 麒麟麦酒株式会社 | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
WO2004024705A1 (ja) | 2002-09-10 | 2004-03-25 | Takeda Pharmaceutical Company Limited | 5員複素環化合物 |
GB0223712D0 (en) | 2002-10-14 | 2002-11-20 | Astrazeneca Ab | Chemical intermediate |
ES2372047T3 (es) | 2002-12-04 | 2012-01-13 | Virginia Commonwealth University | Agentes antidrepanocíticos. |
US6908921B2 (en) | 2002-12-13 | 2005-06-21 | Merck & Co., Inc. | Quinoxalinone derivatives as bradykinin B1 antagonists |
US20040181075A1 (en) | 2002-12-19 | 2004-09-16 | Weingarten M. David | Process of making chalcone derivatives |
US7655633B2 (en) | 2002-12-25 | 2010-02-02 | Kissei Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof |
WO2004073675A1 (de) | 2003-02-24 | 2004-09-02 | Randolph Riemschneider | Kosmetische zusammensetzung mit whitening-effekt, verfahren zu ihrer herstellung und ihre verwendung |
GB0305142D0 (en) | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
US20040186077A1 (en) | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
JPWO2004089410A1 (ja) | 2003-04-03 | 2006-07-06 | 協和醗酵工業株式会社 | 神経因性疼痛の予防及び/または治療剤 |
GB0308333D0 (en) | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
EP1613613B1 (en) | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
WO2004098528A2 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
WO2004111031A1 (en) | 2003-06-12 | 2004-12-23 | Novo Nordisk A/S | Pyridinyl carbamates as hormone-sensitive lipase inhibitors |
US7259164B2 (en) | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
US7411083B2 (en) | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
CA2540647C (en) | 2003-10-01 | 2012-07-10 | Bayer Healthcare Ag | Tetrahydro-naphthalene and urea derivatives |
US7211671B2 (en) | 2003-10-01 | 2007-05-01 | Bristol Myers Squibb Company | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
US20080009478A1 (en) | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
US20080027075A1 (en) | 2003-10-31 | 2008-01-31 | Lica Pharmaceuticals A/S | Quaternary Amino-Function Chalcones |
CN1875002B (zh) | 2003-11-05 | 2011-08-03 | 霍夫曼-拉罗奇有限公司 | 作为ppar激动剂的苯基衍生物 |
AU2004289690A1 (en) | 2003-11-10 | 2005-05-26 | Schering Aktiengesellschaft | Benzylether amine compounds useful as CCR-5 antagonists |
CN1913896B (zh) | 2003-12-02 | 2010-12-01 | 细胞基因公司 | 用于治疗和控制血红蛋白病和贫血病的方法和组合物 |
EP1555264A1 (en) | 2004-01-15 | 2005-07-20 | Sireen AG | Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase. |
US7378439B2 (en) | 2004-01-20 | 2008-05-27 | Usv, Ltd. | Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride |
CA2554120A1 (en) | 2004-01-30 | 2005-08-18 | Merck & Co., Inc. | N-benzyl-3,4-dihydroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integras inhibitors |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
GB0403038D0 (en) | 2004-02-11 | 2004-03-17 | Novartis Ag | Organic compounds |
WO2005087748A1 (en) | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
WO2005086836A2 (en) | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
US20080132458A1 (en) | 2004-03-10 | 2008-06-05 | Threshold Pharmaceuticals, Inc. | Hypoxia-Activated Anti-Cancer Agents |
DE102004015226B3 (de) | 2004-03-24 | 2005-08-25 | Siemens Ag | Verfahren zum Plasmareinigen eines Werkstücks und zu dessen Durchführung geeignete Vorrichtung |
US7297817B2 (en) | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
EP1755592A1 (en) | 2004-04-20 | 2007-02-28 | AB Science | Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy |
WO2005102318A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
WO2005102305A2 (en) * | 2004-04-22 | 2005-11-03 | Allos Therapeutics, Inc. | Compositions of allosteric hemoglobin modifiers and methods of making the same |
WO2005102326A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
JP2007533732A (ja) | 2004-04-23 | 2007-11-22 | アブ サイエンス | 線維症を処置するためのc−kit阻害剤の使用法 |
US20080004279A1 (en) | 2004-04-23 | 2008-01-03 | Alain Moussy | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases |
JP2007538064A (ja) | 2004-05-18 | 2007-12-27 | アブ サイエンス | 化学または生物兵器に曝露された患者を処置するための肥満細胞阻害剤の使用法 |
WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
WO2005115385A1 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
TW200606133A (en) | 2004-06-30 | 2006-02-16 | Sankyo Co | Substituted benzene compounds |
TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006050598A1 (en) | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
WO2006065204A1 (en) | 2004-12-14 | 2006-06-22 | Astrazeneca Ab | Substituted aminopyridines and uses thereof |
US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
WO2006088173A1 (ja) | 2005-02-21 | 2006-08-24 | Shionogi & Co., Ltd. | Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体 |
US7763657B2 (en) | 2005-03-19 | 2010-07-27 | Amorepacific Corporation | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
US7829585B2 (en) | 2005-03-30 | 2010-11-09 | Eisai R&D Management Co., Ltd. | Antifungal agent containing pyridine derivative |
GB0506677D0 (en) | 2005-04-01 | 2005-05-11 | Btg Int Ltd | Iron modulators |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
JP2006306926A (ja) | 2005-04-26 | 2006-11-09 | Fuji Photo Film Co Ltd | 液晶組成物及び液晶素子 |
NZ562339A (en) | 2005-04-28 | 2011-01-28 | Smithkline Beecham Corp | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
WO2006129134A1 (en) | 2005-06-01 | 2006-12-07 | Bioalliance Pharma | Synergic combinations comprising a styrylquinoline compound and other hiv infection therapeutic agents |
AU2006252768A1 (en) | 2005-06-02 | 2006-12-07 | Bayer Cropscience Ag | Phenylalkyl substituted heteroaryl devivatives |
DE102005025989A1 (de) | 2005-06-07 | 2007-01-11 | Bayer Cropscience Ag | Carboxamide |
JP2006342115A (ja) | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Hivインテグラーゼ阻害活性を有する多環性化合物 |
AU2006259938B2 (en) | 2005-06-20 | 2010-07-01 | Astrazeneca Ab | Process for the preparation of sulfonic acid salts of oxabispidines |
NZ564759A (en) * | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
CN100562514C (zh) * | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
GB0516270D0 (en) | 2005-08-08 | 2005-09-14 | Glaxo Group Ltd | Novel compounds |
US7582753B2 (en) | 2005-09-16 | 2009-09-01 | Janssenpharmaceutica, Nv | Process for the preparation of benzotriazepine derivatives |
WO2007047204A1 (en) | 2005-10-11 | 2007-04-26 | University Of Pittsburgh | Isotopically-labeled benzofuran compounds as imagingagents foramyloidogenic proteins |
TW200800988A (en) | 2005-10-27 | 2008-01-01 | Shionogi & Amp Co Ltd | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
US20070197532A1 (en) | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
WO2007081630A2 (en) | 2005-12-21 | 2007-07-19 | Janssen Pharmaceutica, N.V. | Substituted pyrimidinyl kinase inhibitors |
WO2007084914A2 (en) | 2006-01-17 | 2007-07-26 | Neurocrine Biosciences, Inc. | Phenoxy-substituted pyrimidines as adenosine receptor antagonists |
WO2007095495A2 (en) | 2006-02-13 | 2007-08-23 | Pharmacopeia, Inc. | Benzodiazepine gcnf modulators for stem cell modulation |
WO2007095561A2 (en) | 2006-02-15 | 2007-08-23 | Allergan, Inc. | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
WO2007109783A2 (en) | 2006-03-23 | 2007-09-27 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
US7351434B2 (en) | 2006-04-07 | 2008-04-01 | Academia Sinica | Therapeutic Gastrodia extracts |
RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
EP2418210A1 (en) | 2006-04-13 | 2012-02-15 | Vertex Pharmceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
JP4963863B2 (ja) | 2006-04-27 | 2012-06-27 | 株式会社Adeka | 新規化合物及び該化合物を含有してなる液晶組成物 |
US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
EP2044038B1 (en) | 2006-06-06 | 2014-07-02 | Cornerstone Therapeutics Inc. | Novel piperazines, pharmaceutical compositions and methods of use thereof |
BRPI0712430A2 (pt) | 2006-06-08 | 2012-07-03 | Speedel Experimenta Ag | piperidinas 2,5-di-substitìdas. |
GB0614586D0 (en) | 2006-07-22 | 2006-08-30 | Pliva Istrazivacki Inst D O O | Pharmaceutical Formulation |
CN101113148A (zh) | 2006-07-26 | 2008-01-30 | 中国海洋大学 | 二氧哌嗪类化合物及其制备方法和用途 |
AU2007277519B2 (en) | 2006-07-27 | 2011-12-22 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
TWI389895B (zh) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
EP2061749B1 (en) | 2006-09-03 | 2018-02-21 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate |
AU2007303846B2 (en) | 2006-10-04 | 2011-03-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists |
MX2009004385A (es) | 2006-10-23 | 2009-05-22 | Merck & Co Inc | Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide. |
CN101558038B (zh) | 2006-11-30 | 2013-05-01 | 国立大学法人东京工业大学 | 姜黄素衍生物 |
TW200835687A (en) | 2006-11-30 | 2008-09-01 | R Tech Ueno Ltd | Thiazole derivatives and their use as VAP-1 inhibitor |
FR2909379B1 (fr) | 2006-11-30 | 2009-01-16 | Servier Lab | Nouveaux derives heterocycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
DE102006060598A1 (de) | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Tetrahydrobenzoisoxazole |
KR20090101307A (ko) | 2007-01-11 | 2009-09-24 | 알러간, 인코포레이티드 | 스핑고신-1-포스페이트(s1p) 수용체 길항제 생물학적 활성을 갖는 6-치환된 인돌-3-카르복실산 아미드 화합물 |
US8524917B2 (en) | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
US8557853B2 (en) | 2007-02-09 | 2013-10-15 | Allergan, Inc. | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents |
UA109896C2 (xx) | 2007-02-22 | 2015-10-26 | Похідні імінопіридину та їх застосування як мікробіоцидів | |
TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽b2受體調節劑 |
WO2008121066A1 (en) | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | Novel tricyclic spiropiperidines or spiropyrrolidines and their use as modulators of chemokine receptors |
CN101679172B (zh) | 2007-05-22 | 2013-05-29 | 住友化学株式会社 | 苯甲醛化合物的制造方法 |
CN101687790B (zh) | 2007-05-25 | 2015-02-11 | Abbvie公司 | 作为代谢型谷氨酸受体2(mglu2受体)的正向调节剂的杂环化合物 |
WO2009001214A2 (en) | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
US20090069288A1 (en) * | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
ES2423181T3 (es) | 2007-07-17 | 2013-09-18 | F. Hoffmann-La Roche Ag | Inhibidores de la 11ß-hidroxiesteroide-deshidrogenasa |
ATE522249T1 (de) | 2007-07-26 | 2011-09-15 | Novartis Ag | Organische verbindungen |
TW200918521A (en) | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
ES2393430T3 (es) | 2007-10-17 | 2012-12-21 | Novartis Ag | Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK |
JP2009108152A (ja) | 2007-10-29 | 2009-05-21 | Sumitomo Chemical Co Ltd | 重合性化合物および光学フィルム |
AU2008333326B2 (en) | 2007-12-04 | 2013-05-30 | F. Hoffmann-La Roche Ag | Isoxazolo-pyridine derivatives |
US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
JP2009149754A (ja) | 2007-12-20 | 2009-07-09 | Sumitomo Chemical Co Ltd | 重合性化合物および該重合性化合物を重合してなる光学フィルム |
JP2009203230A (ja) | 2008-01-31 | 2009-09-10 | Daiichi Sankyo Co Ltd | ベンジルフェニルグルコピラノシド誘導体を含有する医薬組成物 |
EP2285216A4 (en) | 2008-02-21 | 2012-09-19 | Sequoia Pharmaceuticals Inc | HIV PROTEASE INHIBITOR AND COMBINED CYTOCHROME P450 INHIBITOR |
WO2009106599A2 (en) | 2008-02-29 | 2009-09-03 | Novartis Ag | Substituted piperidines as therapeutic compounds |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
EP2272817A4 (en) | 2008-04-11 | 2011-12-14 | Inst Med Molecular Design Inc | INHIBITOR OF PAI-1 |
US8633245B2 (en) | 2008-04-11 | 2014-01-21 | Institute Of Medicinal Molecular Design, Inc. | PAI-1 inhibitor |
WO2009129267A2 (en) | 2008-04-14 | 2009-10-22 | The Board Of Regents Of The University Of Texas System | Small molecule inhibitors of the pleckstrin homology domain and methods for using same |
JP2011136906A (ja) | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
KR101538822B1 (ko) * | 2008-05-08 | 2015-07-22 | 노바 사우쓰이스턴 유니버시티 | 혈관 내피 성장 인자 수용체에 대한 특이적 억제제 |
WO2009146555A1 (en) | 2008-06-04 | 2009-12-10 | Ambrilia Biopharma Inc. | Hiv integrase inhibitors from pyridoxine |
DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
JP5314330B2 (ja) | 2008-06-16 | 2013-10-16 | 住友化学株式会社 | 2−(アリールオキシメチル)ベンズアルデヒドの製造方法およびその中間体 |
JP2011524917A (ja) | 2008-06-20 | 2011-09-08 | メタボレックス, インコーポレイテッド | アリールgpr119作動薬およびその使用 |
GB0811451D0 (en) * | 2008-06-20 | 2008-07-30 | Syngenta Participations Ag | Novel microbiocides |
ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
WO2010027762A1 (en) | 2008-09-04 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Indolizine inhibitors of leukotriene production |
JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
JP2010066630A (ja) | 2008-09-12 | 2010-03-25 | Sumitomo Chemical Co Ltd | 光学フィルムの製造方法及び光学フィルム |
AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
US8361959B2 (en) | 2008-10-03 | 2013-01-29 | Merck Sharp & Dohme Corp. | Spiro-imidazolone derivatives as glucagon receptor antagonists |
LT3135672T (lt) | 2008-10-10 | 2020-05-25 | Vm Discovery, Inc. | Kompozicijos ir būdai skirti gydyti alkoholio vartojimo sutrikimus, skausmą ir kitas ligas |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
EP2365809B8 (en) | 2008-11-12 | 2018-10-10 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
EP2358716B1 (en) | 2008-11-12 | 2016-01-06 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (fabp) |
AU2009326259A1 (en) | 2008-12-08 | 2011-07-28 | Boehringer Ingelheim International Gmbh | Compounds for treating cancer |
WO2010073011A2 (en) | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
DK2385938T3 (en) | 2009-01-12 | 2015-04-27 | Pfizer Ltd | Sulfonamidderivater |
US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
TW201033201A (en) * | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
TWI482769B (zh) | 2009-03-16 | 2015-05-01 | Sumitomo Chemical Co | 化合物、光學膜片及光學膜片之製造方法 |
JP5899607B2 (ja) | 2009-03-16 | 2016-04-06 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
EP2408753A4 (en) | 2009-03-20 | 2012-11-07 | Univ Brandeis | COMPOUNDS AND METHOD FOR THE TREATMENT OF MICROBIAL STOMACH DARM INFECTIONS IN MAMMALS |
JP2012522058A (ja) | 2009-03-31 | 2012-09-20 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンii受容体アゴニストの経口製剤 |
EP2427190B1 (en) | 2009-05-08 | 2013-09-18 | Tetraphase Pharmaceuticals, Inc. | 8-aza tetracycline compounds |
JP2011006360A (ja) | 2009-06-26 | 2011-01-13 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
WO2011024869A1 (ja) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
EP2474540A4 (en) | 2009-08-31 | 2013-03-13 | Nippon Chemiphar Co | GPR119 AGONIST |
US20120189670A1 (en) | 2009-09-14 | 2012-07-26 | Kirkpatrick D Lynn | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
CN102498100A (zh) | 2009-09-21 | 2012-06-13 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒杂环化合物 |
FI2498756T4 (fi) | 2009-11-09 | 2023-03-22 | Neratinibimaleaatin tablettiformulaatiot | |
TW201139406A (en) | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
CA2786666A1 (en) | 2010-01-25 | 2011-07-28 | Venkateswarulu Akella | Novel compositions for reducing abeta 42 production and their use in treating alzheimer's disease (ad) |
US20130196960A1 (en) | 2010-02-09 | 2013-08-01 | Ironwood Pharmaceuticals, Inc. | Cannabinoid Receptor Agonists |
WO2011100359A1 (en) | 2010-02-09 | 2011-08-18 | Ironwood Pharmaceuticals, Inc. | Cannabinoid agonists |
JP5375644B2 (ja) | 2010-02-10 | 2013-12-25 | 住友化学株式会社 | 組成物及び光学フィルム |
AU2011232675A1 (en) | 2010-03-25 | 2012-09-27 | Merck Sharp & Dohme Corp. | Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use |
CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
KR101698153B1 (ko) | 2010-04-26 | 2017-01-23 | 광주과학기술원 | P2x1 및 p2x3 수용체 길항제로 사용되는 신규한 피리딘 카르복실산계 화합물, 이의 제조방법 및 이를 포함하는 조성물 |
CN102232949A (zh) | 2010-04-27 | 2011-11-09 | 孙远 | 提高药物溶出度的组合物及其制备方法 |
TWI535442B (zh) | 2010-05-10 | 2016-06-01 | Kyowa Hakko Kirin Co Ltd | A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine |
US8969349B2 (en) | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
JP5703594B2 (ja) | 2010-05-26 | 2015-04-22 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
US20130116231A1 (en) | 2010-07-12 | 2013-05-09 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
US20130303761A1 (en) | 2010-09-14 | 2013-11-14 | Instytut Biochemii I Biofizyki Pan | Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction |
CN102116772B (zh) | 2010-09-28 | 2013-08-28 | 上海大学 | 二氢查尔酮化合物的筛选方法 |
JP2013541555A (ja) | 2010-10-21 | 2013-11-14 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 1−(ヘテロ環式カルボニル)−2−置換ピロリジン類 |
CN103313977B (zh) | 2010-10-21 | 2015-06-03 | 拜耳知识产权有限责任公司 | 1-(杂环羰基)哌啶 |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103402500A (zh) | 2010-12-27 | 2013-11-20 | 武田药品工业株式会社 | 口腔崩解片剂 |
EP2663312B1 (en) | 2011-01-10 | 2017-10-11 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
EP2670245B1 (en) | 2011-02-04 | 2015-09-09 | The Scripps Research Institute | Alpha-ketoheterocycles and methods of making and using |
CA2832570A1 (en) | 2011-04-06 | 2012-10-11 | Teva Pharmaceutical Industries Ltd. | New intermediates and processes for preparing ticagrelor |
BR112013025881A2 (pt) | 2011-04-11 | 2017-10-17 | Pharma Eight Co Ltd | composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii) |
KR102104125B1 (ko) | 2011-04-21 | 2020-05-29 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
US8791114B2 (en) | 2011-07-01 | 2014-07-29 | Merck Patent Gmbh | Dihydropyrazoles |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2736887B1 (en) | 2011-07-29 | 2017-10-18 | Karyopharm Therapeutics, Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
US9040520B2 (en) | 2011-09-15 | 2015-05-26 | Demerx, Inc. | Noribogaine salt ansolvates |
US20140308260A1 (en) | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
PT2797416T (pt) | 2011-12-28 | 2017-10-23 | Global Blood Therapeutics Inc | Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
AU2013207972B2 (en) | 2012-01-10 | 2017-06-15 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
BR112014031424A2 (pt) | 2012-06-14 | 2017-06-27 | Janssen Biotech Inc | tratamento de células pluripotentes |
WO2013192517A2 (en) | 2012-06-21 | 2013-12-27 | Whitehead Institute For Biomedical Research | Compounds for treating infectious diseases |
JP2014005380A (ja) | 2012-06-25 | 2014-01-16 | Dic Corp | 液晶組成物 |
CA2878040A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
US9085586B2 (en) | 2012-07-11 | 2015-07-21 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
CA2880178C (en) | 2012-07-27 | 2021-10-26 | Sato Pharmaceutical Co., Ltd. | Difluoromethylene compound |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014031872A2 (en) | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
EP2888256A4 (en) | 2012-08-24 | 2016-02-17 | Univ Texas | HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES |
US9115120B2 (en) | 2012-08-24 | 2015-08-25 | Board Of Regents, The University Of Texas Systems | Heterocyclic modulators of HIF activity for treatment of disease |
NZ704799A (en) | 2012-08-24 | 2018-06-29 | Univ Texas | Heterocyclic modulators of hif activity for treatment of disease |
TW201416348A (zh) | 2012-08-29 | 2014-05-01 | Gruenenthal Chemie | 以氟甲基取代之吡咯甲醯胺 |
JP6117222B2 (ja) | 2012-09-27 | 2017-04-19 | 中外製薬株式会社 | Fgfr3融合遺伝子およびそれを標的とする医薬 |
JP6237646B2 (ja) | 2012-12-27 | 2017-11-29 | 住友化学株式会社 | テトラゾリノン化合物及びその用途 |
US9073946B2 (en) | 2013-01-15 | 2015-07-07 | Kineta, Inc. | Anti-viral compounds |
WO2014130856A2 (en) | 2013-02-21 | 2014-08-28 | Wayne Rothbaum | Treatment of skeletal-related disorders |
US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
MY180206A (en) | 2013-03-15 | 2020-11-25 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
EP2968295A1 (en) | 2013-03-15 | 2016-01-20 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
AP2015008718A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
WO2014150261A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulaton of hemoglobin |
US20150057251A1 (en) | 2013-08-26 | 2015-02-26 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN105073728A (zh) * | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
ES2909634T3 (es) | 2013-03-15 | 2022-05-09 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
US20140271591A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
KR20140127587A (ko) | 2013-04-25 | 2014-11-04 | (주)프론트바이오 | 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
EP2991963B1 (en) | 2013-04-30 | 2021-07-07 | Heinrich-Heine-Universität Düsseldorf | Inhibitors of nhr2 and/or runx1/eto-tetramerization |
WO2014194201A2 (en) | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Cdk8 inhibitors and uses thereof |
WO2014194242A2 (en) | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Flt3 inhibitors and uses thereof |
US20160206604A1 (en) | 2013-08-26 | 2016-07-21 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
US20160207904A1 (en) | 2013-08-27 | 2016-07-21 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
WO2015031285A1 (en) | 2013-08-27 | 2015-03-05 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
KR101628288B1 (ko) | 2013-09-30 | 2016-06-08 | 주식회사 엘지화학 | 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체 |
WO2015051230A1 (en) | 2013-10-04 | 2015-04-09 | Drexel University | Novel compositions useful for inhibiting hiv-1 infection and methods using same |
WO2015058832A1 (en) | 2013-10-21 | 2015-04-30 | Merck Patent Gmbh | Method of preparing a birefringent polymer film |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
US20150141465A1 (en) | 2013-11-18 | 2015-05-21 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN103936659B (zh) | 2013-12-12 | 2016-06-22 | 石家庄诚志永华显示材料有限公司 | 含有碳桥联咔唑结构单元的化合物及其制备方法与应用 |
CN103936658B (zh) | 2013-12-12 | 2016-01-13 | 石家庄诚志永华显示材料有限公司 | 含有咔唑结构单元的化合物及其制备方法与应用 |
EP2883934B1 (en) | 2013-12-16 | 2019-11-13 | Merck Patent GmbH | Liquid-crystalline medium |
US9248199B2 (en) | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
DK3102208T3 (da) | 2014-02-07 | 2021-03-08 | Global Blood Therapeutics Inc | Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd |
DK3110420T3 (da) | 2014-02-25 | 2019-05-13 | Board Of Regents Univ Of Texas System | Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme |
PE20170184A1 (es) | 2014-03-06 | 2017-04-07 | Shanghai Haiyan Pharmaceutical Tech Co Ltd | Derivados de piperidina como antagonista de receptores de orexina |
US20150258104A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Use of noribogaine for the treatment of pain |
US20150258105A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of alcohol dependence |
US20150258106A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of substance abuse |
TWI648282B (zh) | 2014-03-27 | 2019-01-21 | 印度商托仁特生技有限公司 | 新熔合咪唑苯并噻唑化合物 |
EP3157920B1 (en) | 2014-06-17 | 2019-08-07 | Chiesi Farmaceutici S.p.A. | Indolizine derivatives as phosphoinositide 3-kinases inhibitors |
WO2016043849A2 (en) | 2014-07-24 | 2016-03-24 | Global Blood Therapeutics, Inc. | Compounds for treating acute respiratory distress syndrome or a negative effect thereof |
EP3174955B1 (de) | 2014-07-28 | 2019-10-23 | Merck Patent GmbH | Flüssigkristalline medien mit homöotroper ausrichtung |
EP2985334B1 (en) | 2014-08-15 | 2018-06-20 | Merck Patent GmbH | Liquid-crystalline medium |
CN107109227B (zh) | 2014-09-30 | 2021-05-04 | 光学转变公司 | 紫外光吸收剂 |
KR20170065637A (ko) | 2014-10-07 | 2017-06-13 | 세이지 테라퓨틱스, 인크. | 신경활성 화합물 및 그의 사용 방법 |
WO2016077541A1 (en) | 2014-11-12 | 2016-05-19 | The Trustees Of The University Of Pennsylvania | Novel anti-infective compounds and methods using same |
WO2016086194A1 (en) | 2014-11-26 | 2016-06-02 | Demerx, Inc. | Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids |
KR20170117170A (ko) | 2015-02-19 | 2017-10-20 | 퍼듀 퍼머 엘피 | 위 배출을 감소시키기 위한 방법 및 조성물 |
WO2016149248A1 (en) | 2015-03-15 | 2016-09-22 | Emory University | N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto |
WO2016153951A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | 5-deutero-thiazolidinyldione compounds and methods of treating medical disorders using same |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
CN104876912B (zh) | 2015-04-08 | 2017-07-21 | 苏州云轩医药科技有限公司 | Wnt信号通路抑制剂及其应用 |
WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017039318A1 (en) | 2015-09-01 | 2017-03-09 | Kainos Medicine, Inc. | Benzimidazole derivatives for dna methylation inhibitors |
US11124483B2 (en) | 2015-09-02 | 2021-09-21 | The Regents Of The University Of California | HER3 ligands and uses thereof |
TW201711999A (zh) | 2015-09-03 | 2017-04-01 | 佛瑪治療公司 | ﹝6,6﹞稠合雙環組蛋白脫乙醯基酶8(hdac8)抑制劑 |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
JP6919977B2 (ja) | 2016-03-16 | 2021-08-18 | クラ オンコロジー,インク. | メニン−mllの置換された阻害剤及びその使用方法 |
WO2017184531A1 (en) | 2016-04-18 | 2017-10-26 | Demerx, Inc. | Treatment of movement-related disorders using noribogaine |
AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
BR112018076812A2 (pt) | 2016-06-21 | 2021-09-28 | The University Of Melbourne | Ativadores da latência de hiv |
US11746097B2 (en) | 2016-06-24 | 2023-09-05 | Saint Louis University | LXR inverse agonists for treatment of cancer |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
WO2020072377A1 (en) | 2018-10-01 | 2020-04-09 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
PT3880654T (pt) | 2018-11-19 | 2022-04-08 | Global Blood Therapeutics Inc | Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina |
-
2014
- 2014-03-10 CN CN201480015944.4A patent/CN105073728A/zh not_active Withdrawn
- 2014-03-10 ES ES14770695T patent/ES2852054T3/es active Active
- 2014-03-10 BR BR112015021985-3A patent/BR112015021985B1/pt active IP Right Grant
- 2014-03-10 MY MYPI2015002271A patent/MY191087A/en unknown
- 2014-03-10 SG SG11201507320QA patent/SG11201507320QA/en unknown
- 2014-03-10 PE PE2015001922A patent/PE20161035A1/es unknown
- 2014-03-10 CN CN202010996640.8A patent/CN112500338A/zh active Pending
- 2014-03-10 JP JP2016501058A patent/JP6426694B2/ja active Active
- 2014-03-10 CA CA2903220A patent/CA2903220C/en active Active
- 2014-03-10 EP EP14770695.6A patent/EP2970196B1/en active Active
- 2014-03-10 AU AU2014237340A patent/AU2014237340C1/en active Active
- 2014-03-10 AP AP2015008721A patent/AP2015008721A0/xx unknown
- 2014-03-10 US US14/776,726 patent/US20160083343A1/en not_active Abandoned
- 2014-03-10 WO PCT/US2014/022769 patent/WO2014150268A1/en active Application Filing
- 2014-03-10 MX MX2015011445A patent/MX2015011445A/es unknown
- 2014-03-10 KR KR1020157024781A patent/KR102280614B1/ko active IP Right Grant
- 2014-03-10 SG SG10201802911RA patent/SG10201802911RA/en unknown
- 2014-03-10 EA EA201591432A patent/EA034922B1/ru unknown
- 2014-03-13 UY UY0001035426A patent/UY35426A/es not_active Application Discontinuation
- 2014-03-13 TW TW103109178A patent/TWI695830B/zh active
-
2015
- 2015-09-02 IL IL241060A patent/IL241060B/en unknown
- 2015-09-07 CL CL2015002501A patent/CL2015002501A1/es unknown
- 2015-09-09 SA SA517382253A patent/SA517382253B1/ar unknown
- 2015-09-09 SA SA515361026A patent/SA515361026B1/ar unknown
-
2017
- 2017-06-02 ZA ZA2017/03791A patent/ZA201703791B/en unknown
-
2018
- 2018-09-11 US US16/127,776 patent/US20190010121A1/en not_active Abandoned
- 2018-10-25 JP JP2018200506A patent/JP6690861B2/ja active Active
- 2018-11-06 AU AU2018260808A patent/AU2018260808B2/en active Active
- 2018-11-09 US US16/186,275 patent/US11053195B2/en active Active
-
2020
- 2020-04-07 JP JP2020069169A patent/JP2020105228A/ja active Pending
- 2020-06-12 AU AU2020203882A patent/AU2020203882A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160083348A1 (en) * | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
Non-Patent Citations (1)
Title |
---|
Nnamani, I. et al., Chem. & Biodiv. 2008, vol. 5, pp. 1762-69 * |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10377741B2 (en) | 2011-12-28 | 2019-08-13 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
US10822326B2 (en) | 2011-12-28 | 2020-11-03 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
US10806733B2 (en) | 2011-12-28 | 2020-10-20 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
US10034879B2 (en) | 2011-12-28 | 2018-07-31 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
US10100040B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10435393B2 (en) | 2013-03-15 | 2019-10-08 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US11530191B2 (en) | 2013-03-15 | 2022-12-20 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10315991B2 (en) | 2013-03-15 | 2019-06-11 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10017491B2 (en) | 2013-03-15 | 2018-07-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10829470B2 (en) | 2013-03-15 | 2020-11-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9981939B2 (en) | 2013-03-15 | 2018-05-29 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US11236109B2 (en) | 2013-03-15 | 2022-02-01 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US11053195B2 (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10858317B2 (en) | 2013-03-15 | 2020-12-08 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10450269B1 (en) | 2013-11-18 | 2019-10-22 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10722502B2 (en) | 2014-02-07 | 2020-07-28 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
US11452720B2 (en) | 2014-02-07 | 2022-09-27 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
US10137118B2 (en) | 2014-02-07 | 2018-11-27 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
US10695330B2 (en) | 2015-03-30 | 2020-06-30 | Global Blood Therapeutics, Inc. | Methods of treatment |
US10004725B2 (en) | 2015-03-30 | 2018-06-26 | Global Blood Therapeutics, Inc. | Methods of treatment |
US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
US11944612B2 (en) | 2015-12-04 | 2024-04-02 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
US10577345B2 (en) | 2016-05-12 | 2020-03-03 | Global Blood Therapeutics, Inc. | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde |
US10077249B2 (en) | 2016-05-12 | 2018-09-18 | Global Blood Therapeutics, Inc. | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde |
US10493035B2 (en) | 2016-10-12 | 2019-12-03 | Global Blood Therapeutics, Inc. | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
US10683285B2 (en) | 2018-11-19 | 2020-06-16 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
US11548880B2 (en) | 2018-11-19 | 2023-01-10 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
US11014908B2 (en) | 2018-11-29 | 2021-05-25 | Pfizer Inc. | Chemical compounds |
US11702405B2 (en) | 2018-11-29 | 2023-07-18 | Pfizer Inc. | Chemical compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11053195B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
US10450269B1 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
US10858317B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
US11236109B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
US10266551B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
US10100040B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
US9802900B2 (en) | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin | |
US9981939B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
US9604999B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
JP2018188481A (ja) | ヘモグロビンの修飾のための化合物及びその使用 | |
OA17480A (en) | Compounds and uses thereof for the modulation of hemoglobin. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GLOBAL BLOOD THERAPEUTICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:XU, QING;LI, ZHE;GWALTNEY, STEPHEN L., II;SIGNING DATES FROM 20160314 TO 20160316;REEL/FRAME:038053/0691 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |